

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Comparative Evaluation of Novel Screening Strategies for Colorectal Cancer Screening in China (TARGET-C): Study Protocol for a Multicenter Randomized Controlled Trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025935
Article Type:	Protocol
Date Submitted by the Author:	09-Aug-2018
Complete List of Authors:	<p>Chen, Hongda; Chinese Academy of Medical Sciences Cancer Institute and Hospital, Office of cancer screening</p> <p>Li, Ni; Chinese Academy of Medical Sciences Cancer Institute and Hospital, Office of cancer screening</p> <p>Shi, Jufang; National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Cancer Epidemiology;</p> <p>Ren, Jian-song; National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Program Office for Cancer Screening Program in Urban China</p> <p>Liu, Chengcheng; Chinese Academy of Medical Sciences Cancer Institute and Hospital, Office of cancer screening</p> <p>Zhang, Yueming; Chinese Academy of Medical Sciences Cancer Institute and Hospital, Office of cancer screening</p> <p>Jiang, Zheng; Chinese Academy of Medical Sciences Cancer Institute and Hospital</p> <p>Zhang, Zhihui ; National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Cancer Epidemiology</p> <p>Dai, Min; Program Office for Cancer Screening Program in Urban China, National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</p>
Keywords:	Colorectal cancer, Early detection, Risk score, Advanced adenoma

SCHOLARONE™
Manuscripts

1
2
3 **Comparative Evaluation of Novel Screening Strategies for Colorectal Cancer Screening**
4 **in China (TARGET-C): Study Protocol for a Multicenter Randomized Controlled Trial**
5
6
7

8 Hongda Chen^{1*}, Ni Li^{1*}, Jufang Shi¹, Jiansong Ren¹, Chengcheng Liu¹, Yueming
9 Zhang², Zheng Jiang³, Zhihui Zhang⁴, Min Dai¹
10
11
12
13

14 ¹Office of Cancer Screening, National Cancer Center/National Clinical Research
15 Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and
16 Peking Union Medical College, Beijing 100021, China
17
18

19 ²Department of Endoscopy, National Cancer Center/National Clinical Research
20 Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and
21 Peking Union Medical College, Beijing 100021, China
22
23

24 ³ Department of Colorectal Surgery, National Cancer Center/National Clinical
25 Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences
26 and Peking Union Medical College, Beijing 100021, China
27
28

29 ⁴Department of Pathology, National Cancer Center/National Clinical Research
30 Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and
31 Peking Union Medical College, Beijing 100021, China
32
33

34 *Hongda Chen and Ni Li contributed equally to this work.
35
36

37 **Address for Correspondence:** Prof. Min Dai, PhD, National Cancer
38 Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese
39 Academy of Medical Sciences and Peking Union Medical College, Beijing 100021,
40 China; Email: daimin2002@hotmail.com; Tel: +86-10-8778-7394
41
42
43
44

45 **Word account:**3509
46
47
48
49
50
51
52
53
54
55
56
57

Abstract

Introduction: Screening for colorectal cancer (CRC) has been demonstrated to be effective in reducing the burden of this disease. However, high-level evidence from randomized controlled trials on the effectiveness of CRC screening modalities is still lacking. We conducted a large-scale multi-center randomized controlled trial for CRC screening in China to evaluate the effectiveness and cost-effectiveness of different CRC screening strategies in Chinese population.

Methods and analysis: 200,000 eligible participants aged 50-74 years are enrolled in five provinces in China. After getting signed informed consent, the participants will be randomized into one of the three screening groups: 1) one-time colonoscopy (N=4,000); 2) annual FIT (N=8,000); 3) annual risk-adapted screening strategy (N=8,000). For the risk adapted screening strategy, participants will be conducted risk assessment using Asia-Pacific Colorectal Cancer Score. Participants of high-risk for CRC will be referred to colonoscopy and participants of low-risk for CRC will be referred to take FIT. Information on clinical reports, epidemiological risk factors and health economic factors will be collected and stored in a web-based data management system. We further request the participants to donate blood, fecal and saliva samples before conducting colonoscopy. The primary outcome is the detection rate of advanced colorectal neoplasia, and the secondary outcomes include the CRC-related mortality rate, incidence rate of CRC, participation rate and complication rate. The study will last for at least four years and the cohort will be followed for ten years to

1
2
3 adequately answer the scientific questions.
4
5

6
7 **Ethics and dissemination:** This study was approved by Ethics Committee of
8
9 National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and
10
11 Peking Union Medical College (18-013/1615). The results of the study will be
12
13 submitted for publication to peer-reviewed journals and will be discussed by policy
14
15 and decision makers.
16
17

18
19
20 **Trial registration:** Chinese Clinical Trial Registry (ChiCTR1800015506,
21
22 prospectively registered on 3 April 2018).
23

24
25 **Keywords**

26
27 Colorectal cancer, Early detection, Risk score, Advanced adenoma
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- This is the first large-scale population-based colorectal cancer screening trial to compare the effectiveness of three different screening strategies targeting population aged 50 to 74 years old in China.
- Comprehensive health-economic evaluation will be performed to evaluate the cost-effectiveness of different screening arms and policy advices will therefore be provided based on the study findings.
- Prospective biospecimens collected before screening colonoscopy will be valuable resources to explore novel biomarkers for early detection of colorectal cancer in further research.
- The sample sizes of the study population may not be adequate to compare the mortality reduction among the three screening arms after long-term follow-ups.

Introduction

Colorectal Cancer (CRC) is the third most commonly diagnosed cancer and fourth most common cause of cancer worldwide [1]. In China, with an estimate of 376,300 newly diagnosed CRC cases and 191,000 CRC-related deaths in 2015, the incidence ranked the fourth and the mortality ranked the fifth of all cancer types. Notably, the incidence and mortality of CRC has been steadily increasing for the past decades in China [2]. Therefore, establishment of strategies on curbing the rising momentum of CRC in China is strongly required.

Evidences from randomized controlled trials and observational studies have demonstrated that screening could reduce the burden of CRC [3-5]. The established screening modalities include colonoscopy, flexible sigmoidoscopy, and stool-based test (such as fecal occult blood test (FOBT), fecal DNA test), which have been widely used in many screening programs worldwide [6-8]. Colonoscopy is the gold standard for colorectal cancer. However, in population-based screening programs, colonoscopy is limited by low compliance rate, potential complication, high cost and limited resources [9, 10]. Guaiac-based FOBT (gFOBT) was introduced in 1980s. Although the sensitivity of gFOBT for detecting CRC is not optimal, randomized controlled trials demonstrated that screening by gFOBT yielded a reduction of CRC mortality [5]. To date, the newly developed fecal immunochemical test (FIT) for hemoglobin showed superior diagnostic performance than traditional gFOBT [11]. However, evidence from randomized controlled trials to evaluate the screening efficacy of FIT

1
2
3 is still not lacking, especially in Chinese population [11].
4
5

6
7 Current guidelines recommend CRC screening for average-risk population at a start
8
9 age of 50 years old [12-15]. However, in countries having unbalanced and limited
10
11 healthcare resources, identification of high-risk populations and development of
12
13 risk-adapted screening strategies would be potentially more cost-efficient than
14
15 traditional screening strategies. In previous studies, CRC risk scores based on
16
17 environmental and/or generic factors were developed, which typically presented
18
19 moderate diagnostic efficacy [16]. Further combining risk scores with established
20
21 screening modalities such as colonoscopy and FIT was proposed and showed
22
23 promising diagnostic performance [13, 17, 18]. However, further validation of such
24
25 risk-adapted screening strategies in large prospective cohorts and randomized
26
27 controlled trial are still sparse.
28
29
30
31
32
33

34
35 Searching for biomarkers in early detection of CRC is a promising research area.
36
37 Different types of biomarkers, including blood proteins, blood DNA methylation,
38
39 fecal DNA, fecal microbiota and oral microbiota, were reported to be associated with
40
41 CRC and could be potential targets for early detection of CRC [19]. To date, resources
42
43 of biobank using prospectively collected biospecimens from large screening cohorts is
44
45 still lacking. Using the ongoing screening trials to construct the biobank will be both
46
47 time- and economic- saving, which will also be an important platform for biomarker
48
49 identification and validation for further researches.
50
51
52
53

54
55 For China, screening for CRC has been implemented in several regions for the past
56
57

1
2
3 decades [20, 21]. However, high-quality evidence of evidence-based medicine for
4 recommendation of CRC screening for Chinese population is still lacking and highly
5
6 demanding [20]. Therefore, we planned to conduct a population-based, multicenter,
7
8 randomized controlled trial comparing colonoscopy, FIT and a novel risk-adapted
9
10 screening strategy for CRC screening in Chinese population, with the following aims:
11
12
13 1) to establish a large-scale CRC screening cohort with long-term follow-ups in China;
14
15
16 2) to evaluate the effectiveness and cost-effectiveness of different CRC screening
17
18 strategies in Chinese population; 3) to construct a large epidemiological and clinical
19
20 database and a biobank for further studies.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods/Design

Study setting and design

This is a prospective, multicenter, randomized controlled trial comparing multiple screening strategies on colorectal cancer screening in China. Participants who meet the study inclusion and exclusion criteria are recruited in five provinces in China. We aim to recruit at least 20,000 eligible participants at baseline. After obtaining signed informed consent, eligible participants are randomly allocated into one of the following three colorectal cancer screening groups in a 1:2:2 ratio (Figure 1). The study will be conducted for at least four years (including one year for baseline screening and at least three-year follow-ups) and the follow-up will be conducted at least ten years until the scientific questions are answered adequately.

- 1) ***Colonoscopy group (N=4,000)***: participants are recommended to undertake one-time screening colonoscopy at baseline. Participants with abnormal findings during colonoscopy are conducted further pathology examination. For the following years, all the participants will be interviewed by the follow-up questionnaire annually.
- 2) ***FIT group (N=8,000)***: FITs are offered to the participants annually. Participants who have positive FIT results are recommended to take screening colonoscopy. Participants with abnormal findings during colonoscopy are conducted further pathology examination.
- 3) ***Risk assessment group (N=8,000)***: Colorectal cancer risk are assessed using an

1
2
3 established colorectal cancer risk stratification score system at baseline. For
4 participants with high risk of colorectal cancer, screening colonoscopy are
5 offered. For participants with low risk of colorectal cancer, FITs are offered and
6 those with positive FIT results are recommended to take further colonoscopy.
7
8 During the annual follow-ups, participants who have negative FIT results and
9 participants who have not taken screening colonoscopy will conducted another
10 round of risk assessment and the same screening procedures as baseline
11 intervention will be conducted. For participants who have already undertaken
12 screening colonoscopy, no further screening intervention will be provided but
13 will be interviewed by questionnaire annually during the study period.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Randomization and allocation procedure

29
30 The randomization is conducted in a centralized controlled manner. The leading
31 institute (Cancer Hospital, Chinese Academy of Medical Sciences) is responsible for
32 the generation of randomization scheme using a predefined seed by the statistical
33 software R. Before recruitment, the staffs who are responsible for the recruitment at
34 each site and the participants are blinded to the allocation results. The allocation
35 results are revealed after successful registration of the subject in a web-based data
36 system. At the time of randomization, a unique Study Identification Number (SIN) is
37 allocated to the participant and will be the used for the participants during the entire
38 study period.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

Study population and recruitment

1
2
3
4 Participants aged 50 to 74 years who are habitant of the study region and are able to
5
6 sign informed consent are eligible for this study. Exclusion criteria are: 1) prior
7
8 history of colorectal cancer; 2) prior history of colonic resection; 3) undertaking any
9
10 kind of cancer related therapy (except for non-melanoma skin cancer); 4) prior
11
12 colonic examination, including colonoscopy, flexible sigmoidoscopy, CT colonography
13
14 and Barium enema within five years; 5) prior history of fecal occult blood test and
15
16 Barium enema within five years; 5) prior history of fecal occult blood test and
17
18 fecal DNA test within 1 year; 6) symptoms of lower gastrointestinal tract disease
19
20 warranting colonoscopic evaluation, including: a) more than one episode of rectal
21
22 bleeding within the past 6 months; b) documented iron deficiency anemia; c)
23
24 significant documented unintentional weight loss (>10% of baseline weight) over 6
25
26 months; 7) significant comorbidity that would preclude benefit from screening or pose
27
28 significant risk for the performance of colonoscopy (e.g. severe lung disease,
29
30 end-stage renal disease, end-stage liver disease, severe heart failure, recent diagnosis
31
32 of cancer (with the exception of non-melanoma skin cancer).
33
34
35
36
37
38

39 Recruitment procedures will involve the following steps:

- 40
41 (1) Recruitment of potential participants aged 50 to 75 years in selected
42
43 communities and check for eligibility by trained study staff;
44
45
- 46 (2) Signed written informed consent obtained from the eligible participants by
47
48 trained study staffs;
49
50
- 51 (3) Subjects registration in the web-based data management system, SIN
52
53 allocated, and randomization results revealed;
54
55
- 56 (4) Conducting respective intervention strategies per protocol;
57
58

Interventions

Colonoscopy

Standard clinical procedures of the screening colonoscopy will be followed, including appointment, obtaining informed consent, routine blood test for infectious diseases including hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections, distribution of bowel preparation drugs, diet control, anesthesia (if required by the participants) and colonoscopy examination. Colonoscopy will be performed by experienced endoscopists who are attending physician or above and have more than five-year working experiences for colonoscopy. Abnormal findings during colonoscopy are carefully checked under standard clinical procedures and tissue specimens are collected for further pathology diagnosis. Any findings during colonoscopy are required to be photo documented. Clinical information such as time of examination duration, sedation status, completeness, bowel preparation status, complication, polyp feature (such as number, position, size, color and shape), description of other abnormal findings than polyp, as well as pathology diagnosis will be collected and documented in the web-based data management system.

For quality control, expert panel including experienced endoscopists and pathologist will be formed. Each year, a selection of colonoscopy and pathology documentation will be assessed by the expert panel, and review reports will be transferred to the respective physicians about their performance.

Fecal immunochemical test (FIT)

Fecal immunochemical tests for human hemoglobin are provided by the study staff to participants for after the successful registration of this study. The FIT used in this study is a self-administered qualitative test, providing an endpoint that is read as positive or negative by eye if the fecal hemoglobin concentration exceeds the manufacturer-specific threshold. The participants can submit the results to the study website along with the pictures of test window or will be interviewed by the study staff for the test results within three days of distributing the FIT. For participants having invalid test results, new test devices are provided until getting valid test results. Participants are contacted and arranged for following colonoscopy if they are confirmed to have positive FIT results.

Colorectal cancer risk assessment

In this study, an established colorectal cancer risk score system, Asia-Pacific Colorectal Cancer (APCS) score [22, 23], will be used. The APCS score is derived based on five common risk factors of colorectal cancer, including age, gender, family history of colorectal cancer in a first-degree relative and smoking. Detailed information of the APCS score is shown in Table 1. Generally, for the risk-adapted screening group (risk assessment group), participants are asked to filled in a questionnaire including the above mentioned risk factors, participants with a score ≥ 4 are defined as high-risk of colorectal cancer with the others being defined as low-risk of colorectal cancer. Participants will be informed about their evaluation results and receive respective screening intervention per study protocol.

Biospecimen collection and handling

Participants who need to undertake colonoscopy are invited to donate stool, saliva and blood samples prior to colonoscopy. Standard Operating Procedures (SOPs) regarding biospecimen collection, handling and storage have been formulated and will be followed.

For stool samples, collection devices (including sample collection vials, ice bags, isothermal bags and operation brochures) are distributed. At the day before colonoscopy, participants are suggested to collect raw stool samples before taking bowel cleaning drugs for colonoscopy. The participants are recommended to store the samples in the freezer or in the isothermal bags with ice bags until transported to the hospital. The samples are stored in the freezer (-80°C) immediately for future use when received.

For saliva samples, participants are provided with samples collection tubes (with oral DNA stabilization buffer) during their visit of hospital before colonoscopy. Study staffs will guide the participants for the saliva sample collection procedure. Collected samples will be aliquoted immediately and stored in the freezer (-80°C) for future use.

For blood samples, around 10ml vein blood samples (including 5ml EDTA anticoagulated blood and 5ml non-anticoagulation blood) are withdrawn from the participants during their visit of the hospital before colonoscopy. Under the SOPs, blood samples are centrifuged, aliquoted and then stored in the freezer (-80°C) for future use.

Follow up

Both active follow-up and passive follow-up will be conducted in this study. For the active follow-up, all the participants will be interviewed by trained study staff by telephone call, home visit or other contact methods for collection information such as diagnostic examination, health status and outcome. For the passive follow-up, linkage data from cancer registry system, death surveillance system, medical insurance and claim databased will be used to track the outcome of the participants as supplement.

Contamination evaluation

During the study period, study team will contact the participants to evaluate the status of colorectal cancer beyond the study protocol. The extra screening examinations conducted by the participant during the study period are not allocated by the randomization, and therefore may introduce contamination to the study results. To evaluate the contamination status of this study, all the participant who are screened to have negative findings will be conducted one round of questionnaire interview in the fourth year of the study. Information regarding the history of diagnostic or screening colonic examination will be collected and assessed. We anticipate controlling the contamination rate to be below 10%. For the final analysis report, the contamination will be taken into consideration to estimate the screening effects.

Outcome measures

The primary outcome is the detection rate of advanced colorectal neoplasia (i.e., colorectal cancer and advanced adenoma). The secondary outcomes include mortality rate of colorectal cancer, incidence rate of colorectal cancer, participation rate,

1
2
3 complication rate.
4
5

6 7 ***Data collection***

8 9 *Epidemiological risk factor investigation*

10
11 A standardized epidemiological questionnaire will be administered by trained
12
13 interviewers for all participants to investigate the risk factors of colorectal cancer.
14
15 Information including sociodemographic factors, history of bowel disease and clinical
16
17 treatment, living habits, disease history and family history of cancer are collected and
18
19 stored in the web-based data management system.
20
21
22

23 24 *Health economic information*

25
26 Comprehensive health economic evaluation will be conducted. Questionnaires
27
28 including EuroQol five dimensions questionnaire (EQ-5D) and EQ-5D-3L will be
29
30 used to measure health state of the participants. The direct costs on materials,
31
32 equipment, personnel, drug and other resources will be collected from all participating
33
34 sites to estimate the cost-effectiveness of different screening strategies in this clinical
35
36 trial.
37
38
39
40
41

42 43 ***Statistical Considerations***

44 45 *Sample size*

46
47 Sample sizes were calculated based on the evaluation of primary outcomes, i.e.,
48
49 advanced neoplasia detection rate (ADR). The hypothesis was that the ADR of
50
51 risk-adapted screening group was superior to the FIT group and non-inferior to the
52
53 colonoscopy group. According to the previous studies, the ADR of colonoscopy, FIT
54
55
56

1
2
3 and risk-adapted screening groups were 6.5%, 1.8% and 5.0% [13, 24]. We assumed
4
5 the compliance rate was 50% to 70% for colonoscopy, 60%-90% for FIT and 60%-90%
6
7 for the risk-adapted screening strategy and an overall loss-to-follow-up of 10%. For
8
9 the comparison between the risk-adapted screening strategy and FIT group at different
10
11 scenarios of the compliance rates, the largest sample size needed was 6550 when we
12
13 set the significance level of $\alpha=0.05$, the power of 0.8 and superiority margin (δ) of
14
15 -0.005. For the comparison between the risk-adapted screening group and
16
17 colonoscopy group, when assuming the respective compliance rates were 85% and
18
19 60%, the required sample sizes were 6032 and 3016, respectively, when we set the
20
21 significance level of $\alpha=0.05$, the power of 0.8, non-inferiority margin (δ) of -0.001.
22
23 Therefore, the sample sizes of this study design (4000 for the colonoscopy group,
24
25 8000 for the FIT group and 8000 for the risk-adapted screening group) will
26
27 accomplish the study hypotheses.
28
29
30
31
32
33
34
35

36 *Statistical analyses*

37
38 The primary outcome analysis will be a comparison of histologically confirmed
39
40 colorectal cancer and advanced adenoma between the three intervention arms taking
41
42 into consideration of compliance rate. Intention-to-treat and per-protocol analyses will
43
44 be conducted. For secondary outcomes, mortality rate will be calculated as the ratio of
45
46 the number of death due to colorectal cancer to the person-year at risk for each group.
47
48 Person-years will be estimated from the time of randomization to the diagnosis date of
49
50 colorectal cancer, death or censoring at the end of the study. Incidence rate will be
51
52 estimated in a similar way. Chi-square tests and t-tests are used to compare categorical
53
54
55
56
57
58
59
60

1
2
3 and continuous variables between the two groups, respectively. The Cox proportional
4
5 hazards regression model is adopted to examine the difference of incidence and
6
7 mortality between different screening groups. For health economic evaluation,
8
9 Markov model will be developed to evaluate the cost-effectiveness of different
10
11 screening strategies for colorectal cancer in China. Statistical software, such as SAS
12
13 software (version 9.2; SAS Institute, Cary, NC, USA), R (version 3.4.1, R Foundation
14
15 for Statistical Computing, Vienna, Austria) and TreeAge Pro 2016 (TreeAge Software,
16
17 Inc., MA, USA), will be used in the data analyses.
18
19
20
21
22
23
24
25

26 **Ethics and dissemination**

27
28
29 This study was approved by Ethics Committee of National Cancer Center/Cancer
30
31 Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
32
33 (approved number:18-013/1615) and the protocol was registered in the Chinese
34
35 Clinical Trial Registry (registration number: ChiCTR1800015506).
36
37
38

39
40 The results of the study will be submitted for publication to peer-reviewed journals
41
42 and conferences following the Consolidated Standards of Reporting Trials guidelines.
43
44

45 The results will be discussed by policy and decision makers. Access to the detailed
46
47 research plan, participant-level dataset and statistical analysis code will be granted
48
49 based on reasonable requests after the publication of the study.
50
51

52 ***Trial status***

53
54 This screening trial is currently in the participant enrolment phase. 1600 eligible
55
56
57
58
59
60

1
2
3 participants have been randomised and are under respective colorectal cancer
4
5 screening at August 2018. We anticipate the full analysis will be finalised in
6
7
8 December 2021.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Discussion

Our study aims at evaluation the effectiveness and cost-effectiveness of three strategies for CRC screening in China. To our knowledge, this is the first large-scale randomized controlled trial on CRC screening based on community population in China. Colonoscopy is the gold standard for CRC screening, and FIT is the most widely used non-invasive CRC screening test. However, the magnitude of the effect of colonoscopy and FIT in population-based CRC screening is uncertain due to lack of evidence from randomized controlled trial. To date, there are four large-scale randomized controlled trials (NordICC, SCREESCO, CONFIRM and COLONPREV) comparing colonoscopy or FIT screening with regard to CRC incidence and mortality [25-28]. All the four trials are currently ongoing and conducted in Europe and North America. Our study will be the first large-scale CRC screening trial in Asia. In addition, we also include a novel risk-adapted screening strategy in our trial, which incorporates risk assessment with established screening methods. Our study will provide strong evidence on the effectiveness and feasibility of different strategies for CRC screening in China.

In recent years, the burden of CRC has been increasing in East-Asia which has been explained by changes in diet and a westernized lifestyle [29]. Countries including China, Japan and South Korea have implemented organized screening programs. For instance, in Japan, the CRC screening program was initiated since 1992 which uses FIT as the main screening method and the cost is covered by the national health

1
2
3 insurance [30]. In China, individuals aged 40-74 years are screened with FOBT or
4
5
6 colonoscopy based on clinical risk indexes in some regions but not the entire country
7
8 [20]. Furthermore, the most appropriate techniques for different populations in China
9
10 are still under debate. The results of our study will therefore provide high-level
11
12 evidence to aid for high demanding on the prevention and screening strategy for
13
14 China and provides essential references for other countries.
15
16
17
18

19 In this study, we plan to finish the baseline recruitment and screening at the end of
20
21 2018 and continue long-term follow-up to evaluate the long-term effect of screening.
22
23 There are several strengths for our study. Firstly, we use a prospective randomized
24
25 design which would minimize the selection bias and provide high-level evidence
26
27 compared to other study designs such as cross-sectional studies. In addition, except
28
29 for active follow-up, we will use multiple resources such as cancer registry, death
30
31 surveillance system, medical insurance and claim databases to track the outcomes of
32
33 all the study participants. We will also construct a large biobank using prospectively
34
35 collected specimens. Such biobank will serve as an essential platform for biomarker
36
37 identification and validation for further researches.
38
39
40
41
42
43
44

45 The major challenges of this study are the control of loss to follow-up and the quality
46
47 control of multi-center project. To address such concern, we will employ experienced
48
49 study staff to contact and visit the participants regularly. Moreover, health education
50
51 campaign will be conducted to improve the health literacy by means of lectures,
52
53 videos, advertisement and social media. For the quality control, we will build an
54
55
56
57
58
59
60

1
2
3 expert panel including experts of epidemiologist, endoscopiest, pathologist and
4
5
6 surgeons. Capacity training workshop will be held annually, and selection of study
7
8 reports will be reviewed to ensure the study quality.
9

10
11 To sum up, this is a large-scale multi-center randomized controlled trials on
12
13 comparing three strategies for CRC screening. Successful implementation of this
14
15 study will provide strong evidence on the effectiveness and cost-effectiveness of CRC
16
17 screening and provide essential references for policy-makers to design national
18
19 screening programs in the future.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Authors' contributions

HC, NL and MD designed the study protocol, HC and NL drafted the manuscript, JR, CL, YZ, ZJ, ZZ and MD critically reviewed and revised the manuscript. All authors read and approved the final manuscript.

Funding statement:

This study was sponsored by CAMS Innovation Fund for Medical Sciences (2017-I2M-1-006) and National Natural Science Foundation of China (81703309).

The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Competing interests

The authors declare that they have no competing interests.

Acknowledgements

The authors would like to thank all participating sites: Zhejiang Cancer Hospital, Anhui Provincial Cancer Hospital, Xuzhou Cancer Hospital, Hunan Cancer Hospital, Yunnan Cancer Hospital, Center for Disease Control and Prevention of the participating cities and the community staffs for their contribution.

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, and Jemal A, Global cancer statistics, 2012. *CA Cancer J Clin*, 2015. 65(2): 87-108.
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, and He J, Cancer statistics in China, 2015. *CA Cancer J Clin*, 2016. 66(2): 115-32.
3. Zorzi M, Fedeli U, Schievano E, Bovo E, Guzzinati S, Baracco S, Fedato C, Saugo M, and Dei Tos AP, Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test. *Gut*, 2015. 64(5): 784-90.
4. Brenner H, Stock C, and Hoffmeister M, Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. *Bmj*, 2014. 348: g2467.
5. Hewitson P, Glasziou P, Watson E, Towler B, and Irwig L, Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. *Am J Gastroenterol*, 2008. 103(6): 1541-9.
6. Brenner H, Kloor M, and Pox CP, Colorectal cancer. *Lancet*, 2014. 383(9927): 1490-502.
7. Schreuders EH, Ruco A, Rabeneck L, Schoen RE, Sung JJ, Young GP, and Kuipers EJ, Colorectal cancer screening: a global overview of existing programmes. *Gut*, 2015. 64(10): 1637-49.
8. Whitlock EP, Lin JS, Liles E, Beil TL, and Fu R, Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. *Ann Intern Med*, 2008. 149(9): 638-58.
9. Senore C, Inadomi J, Segnan N, Bellisario C, and Hassan C, Optimising colorectal cancer screening acceptance: a review. *Gut*, 2015. 64(7): 1158-77.
10. Robertson DJ, Kaminski MF, and Bretthauer M, Effectiveness, training and quality assurance of colonoscopy screening for colorectal cancer. *Gut*, 2015. 64(6): 982-90.
11. Tinmouth J, Lansdorp-Vogelaar I, and Allison JE, Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know. *Gut*, 2015. 64(8): 1327-37.
12. Lin JS, Piper MA, Perdue LA, Rutter CM, Webber EM, O'Connor E, Smith N, and Whitlock EP, Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *Jama*, 2016. 315(23): 2576-94.

13. Chiu HM, Ching JY, Wu KC, Rerknimitr R, Li J, Wu DC, Goh KL, Matsuda T, Kim HS, Leong R, Yeoh KG, Chong VH, Sollano JD, Ahmed F, Menon J, and Sung JJ, A Risk-Scoring System Combined With a Fecal Immunochemical Test Is Effective in Screening High-Risk Subjects for Early Colonoscopy to Detect Advanced Colorectal Neoplasms. *Gastroenterology*, 2016. 150(3): 617-25.e3.
14. Provenzale D, Jasperson K, Ahnen DJ, Aslanian H, Bray T, Cannon JA, David DS, Early DS, Erwin D, Ford JM, Giardiello FM, Gupta S, Halverson AL, Hamilton SR, Hampel H, Ismail MK, Klapman JB, Larson DW, Lazenby AJ, Lynch PM, Mayer RJ, Ness RM, Rao MS, Regenbogen SE, Shike M, Steinbach G, Weinberg D, Dwyer MA, Freedman-Cass DA, and Darlow S, Colorectal Cancer Screening, Version 1.2015. *J Natl Compr Canc Netw*, 2015. 13(8): 959-68; quiz 68.
15. Armaroli P, Villain P, Suonio E, Almonte M, Anttila A, Atkin WS, Dean PB, de Koning HJ, Dillner L, Herrero R, Kuipers EJ, Lansdorp-Vogelaar I, Minozzi S, Paci E, Regula J, Tornberg S, and Segnan N, European Code against Cancer, 4th Edition: Cancer screening. *Cancer Epidemiol*, 2015. 39 Suppl 1: S139-52.
16. Win AK, Macinnis RJ, Hopper JL, and Jenkins MA, Risk prediction models for colorectal cancer: a review. *Cancer Epidemiol Biomarkers Prev*, 2012. 21(3): 398-410.
17. Jung YS, Park CH, Kim NH, Park JH, Park DI, and Sohn CI, A combination of clinical risk stratification and fecal immunochemical test is useful for identifying persons with high priority of early colonoscopy. *Dig Liver Dis*, 2018. 50(3): 254-59.
18. Cubiella J, Digby J, Rodriguez-Alonso L, Vega P, Salve M, Diaz-Ondina M, Strachan JA, Mowat C, McDonald PJ, Carey FA, Godber IM, Younes HB, Rodriguez-Moranta F, Quintero E, Alvarez-Sanchez V, Fernandez-Banares F, Boadas J, Campo R, Bujanda L, Garayoa A, Ferrandez A, Pinol V, Rodriguez-Alcalde D, Guardiola J, Steele RJ, and Fraser CG, The fecal hemoglobin concentration, age and sex test score: Development and external validation of a simple prediction tool for colorectal cancer detection in symptomatic patients. *Int J Cancer*, 2017. 140(10): 2201-11.
19. Dickinson BT, Kisiel J, Ahlquist DA, and Grady WM, Molecular markers for colorectal cancer screening. *Gut*, 2015. 64(9): 1485-94.
20. Goss PE, Strasser-Weippl K, Lee-Bychkovsky BL, Fan L, Li J, Chavarri-Guerra Y, Liedke PE, Pramesh CS, Badovinac-Crnjevic T, Sheikine Y, Chen Z, Qiao YL, Shao Z, Wu YL, Fan D, Chow LW, Wang J, Zhang Q, Yu S, Shen G, He J, Purushotham A, Sullivan R, Badwe R, Banavali SD, Nair R,

- 1
2
3 Kumar L, Parikh P, Subramanian S, Chaturvedi P, Iyer S, Shastri SS,
4 Digumarti R, Soto-Perez-de-Celis E, Adilbay D, Semiglazov V, Orlov S,
5 Kaidarova D, Tsimafeyeu I, Tatishchev S, Danishevskiy KD, Hurlbert M, Vail
6 C, St Louis J, and Chan A, Challenges to effective cancer control in China,
7 India, and Russia. *Lancet Oncol*, 2014. 15(5): 489-538.
8
9
10 21. Guo C, Liu Q, and Dai M, [Colorectal cancer screening: situation and
11 prospect]. *Zhonghua Yu Fang Yi Xue Za Zhi*, 2015. 49(5): 377-80.
12
13 22. Sung JJY, Wong MCS, Lam TYT, Tsoi KKF, Chan VCW, Cheung W, and
14 Ching JYL, A modified colorectal screening score for prediction of advanced
15 neoplasia: A prospective study of 5744 subjects. *J Gastroenterol Hepatol*, 2018.
16 33(1): 187-94.
17
18 23. Yeoh KG, Ho KY, Chiu HM, Zhu F, Ching JY, Wu DC, Matsuda T, Byeon JS,
19 Lee SK, Goh KL, Sollano J, Rerknimitr R, Leong R, Tsoi K, Lin JT, and Sung
20 JJ, The Asia-Pacific Colorectal Screening score: a validated tool that stratifies
21 risk for colorectal advanced neoplasia in asymptomatic Asian subjects. *Gut*,
22 2011. 60(9): 1236-41.
23
24 24. Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP,
25 Ahlquist DA, and Berger BM, Multitarget stool DNA testing for
26 colorectal-cancer screening. *N Engl J Med*, 2014. 370(14): 1287-97.
27
28 25. Kaminski MF, Bretthauer M, Zauber AG, Kuipers EJ, Adami HO, van
29 Ballegooijen M, Regula J, van Leerdam M, Stefansson T, Pahlman L, Dekker
30 E, Hernan MA, Garborg K, and Hoff G, The NordICC Study: rationale and
31 design of a randomized trial on colonoscopy screening for colorectal cancer.
32 *Endoscopy*, 2012. 44(7): 695-702.
33
34 26. Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanás A, Andreu M,
35 Carballo F, Morillas JD, Hernandez C, Jover R, Montalvo I, Arenas J, Laredo
36 E, Hernandez V, Iglesias F, Cid E, Zubizarreta R, Sala T, Ponce M, Andres M,
37 Teruel G, Peris A, Roncales MP, Polo-Tomas M, Bessa X, Ferrer-Armengou O,
38 Grau J, Serradesanferm A, Ono A, Cruzado J, Perez-Riquelme F,
39 Alonso-Abreu I, de la Vega-Prieto M, Reyes-Melian JM, Cacho G,
40 Diaz-Tasende J, Herreros-de-Tejada A, Poves C, Santander C, and
41 Gonzalez-Navarro A, Colonoscopy versus fecal immunochemical testing in
42 colorectal-cancer screening. *N Engl J Med*, 2012. 366(8): 697-706.
43
44 27. CONFRIM trial at <http://www.clinicaltrials.gov/ct2/show/NCT01239082>
45 (accessed 28 April 2018).
46
47 28. Screesco trial at <http://www.clinicaltrials.gov/ct2/show/NCT02078804>
48 (accessed 28 April 2018).
49
50 29. Sung JJ, Lau JY, Goh KL, and Leung WK, Increasing incidence of colorectal
51 cancer in Asia: implications for screening. *Lancet Oncol*, 2005. 6(11): 871-6.
52
53
54
55
56
57
58
59
60

- 1
2
3 30. Saito H, Colorectal cancer screening using immunochemical faecal occult
4 blood testing in Japan. J Med Screen, 2006. 13 Suppl 1: S6-7.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Risk factors included in the colorectal cancer risk assessment score


Risk factor	Criteria	Points
Age (years)	<50	0
	50-69	1
	≥70	2
Gender	Female	0
	Male	1
Family history of colorectal cancer in a first-degree relative	Absent	0
	Present	1
Smoking	No	0
	Current or past	1
BMI	<23	0
	≥23	1

Figure Legend

Figure 1. SPIRIT flow diagram of the study design

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SPIRIT flow diagram of the study design

338x190mm (96 x 96 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Page
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	4
	2b	All items from the World Health Organization Trial Registration Data Set	4
Protocol version	3	Date and version identifier	NA
Funding	4	Sources and types of financial, material, and other support	22
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	22
	5b	Name and contact information for the trial sponsor	NA
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	22
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	11
Introduction			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	5
	6b	Explanation for choice of comparators	5 and 6
Objectives	7	Specific objectives or hypotheses	5 and 6
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	7

Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	8
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	10
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	8 and 9
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	10
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	10
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	11
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	14
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	8
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	15
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	10

Methods: Assignment of interventions (for controlled trials)

Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	9
---------------------	-----	--	---

1	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central	9
2	concealment		telephone; sequentially numbered, opaque, sealed envelopes),	
3	mechanism		describing any steps to conceal the sequence until interventions are	
4			assigned	
5				
6				
7	Implementation	16c	Who will generate the allocation sequence, who will enrol participants,	9
8			and who will assign participants to interventions	
9				
10	Blinding	17a	Who will be blinded after assignment to interventions (eg, trial	9
11	(masking)		participants, care providers, outcome assessors, data analysts), and	
12			how	
13				
14		17b	If blinded, circumstances under which unblinding is permissible, and	9
15			procedure for revealing a participant's allocated intervention during	
16			the trial	
17				

18 **Methods: Data collection, management, and analysis**

19				
20	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other	15
21	methods		trial data, including any related processes to promote data quality (eg,	
22			duplicate measurements, training of assessors) and a description of	
23			study instruments (eg, questionnaires, laboratory tests) along with	
24			their reliability and validity, if known. Reference to where data	
25			collection forms can be found, if not in the protocol	
26				
27				
28		18b	Plans to promote participant retention and complete follow-up,	13
29			including list of any outcome data to be collected for participants who	
30			discontinue or deviate from intervention protocols	
31				
32	Data	19	Plans for data entry, coding, security, and storage, including any	15
33	management		related processes to promote data quality (eg, double data entry;	
34			range checks for data values). Reference to where details of data	
35			management procedures can be found, if not in the protocol	
36				
37	Statistical	20a	Statistical methods for analysing primary and secondary outcomes.	16
38	methods		Reference to where other details of the statistical analysis plan can be	
39			found, if not in the protocol	
40				
41				
42		20b	Methods for any additional analyses (eg, subgroup and adjusted	16
43			analyses)	
44				
45		20c	Definition of analysis population relating to protocol non-adherence	16
46			(eg, as randomised analysis), and any statistical methods to handle	
47			missing data (eg, multiple imputation)	
48				

49 **Methods: Monitoring**

50				
51	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role	11
52			and reporting structure; statement of whether it is independent from	
53			the sponsor and competing interests; and reference to where further	
54			details about its charter can be found, if not in the protocol.	
55			Alternatively, an explanation of why a DMC is not needed	
56				
57				
58				
59				

1		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	NA
2				
3				
4				
5				
6	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	15
7				
8				
9				
10	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	NA
11				
12				
13				
14	Ethics and dissemination			
15				
16	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	17
17				
18				
19	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	17
20				
21				
22				
23				
24	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	10
25				
26				
27				
28		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	13
29				
30	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	9
31				
32				
33				
34				
35	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	22
36				
37				
38	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	9
39				
40				
41				
42	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	NA
43				
44				
45	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	NA
46				
47				
48				
49				
50				
51		31b	Authorship eligibility guidelines and any intended use of professional writers	NA
52				
53				
54		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	NA
55				
56				
57				
58				
59				
60				

Appendices

Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	NA
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	13

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.

BMJ Open

Comparative Evaluation of Novel Screening Strategies for Colorectal Cancer Screening in China (TARGET-C): Study Protocol for a Multicenter Randomized Controlled Trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025935.R1
Article Type:	Protocol
Date Submitted by the Author:	12-Dec-2018
Complete List of Authors:	Chen, Hongda; Chinese Academy of Medical Sciences Cancer Institute and Hospital, Office of cancer screening Li, Ni; Chinese Academy of Medical Sciences Cancer Institute and Hospital, Office of cancer screening Shi, Jufang; National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Department of Cancer Epidemiology; Ren, Jian-song; National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Program Office for Cancer Screening Program in Urban China Liu, Chengcheng; Chinese Academy of Medical Sciences Cancer Institute and Hospital, Office of cancer screening Zhang, Yueming; Chinese Academy of Medical Sciences Cancer Institute and Hospital, Office of cancer screening Jiang, Zheng; Chinese Academy of Medical Sciences Cancer Institute and Hospital Zhang, Zhihui ; National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Department of Cancer Epidemiology Dai, Min; Program Office for Cancer Screening Program in Urban China, National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Primary Subject Heading:	Oncology
Secondary Subject Heading:	Epidemiology, Gastroenterology and hepatology, Health economics, Public health
Keywords:	Colorectal cancer, Early detection, Risk score, Advanced adenoma, Randomized controlled trial

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Comparative Evaluation of Novel Screening Strategies for Colorectal Cancer**
5 **Screening in China (TARGET-C): Study Protocol for a Multicenter Randomized**
6 **Controlled Trial**
7
8
9

10
11 Hongda Chen^{1*}, Ni Li^{1*}, Jufang Shi¹, Jiansong Ren¹, Chengcheng Liu¹, Yueming
12 Zhang², Zheng Jiang³, Zhihui Zhang⁴, Min Dai¹
13
14
15

16
17 ¹Office of Cancer Screening, National Cancer Center/National Clinical Research
18 Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking
19 Union Medical College, Beijing 100021, China
20
21

22
23 ²Department of Endoscopy, National Cancer Center/National Clinical Research Center
24 for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union
25 Medical College, Beijing 100021, China
26
27

28
29 ³ Department of Colorectal Surgery, National Cancer Center/National Clinical
30 Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences
31 and Peking Union Medical College, Beijing 100021, China
32
33

34
35 ⁴Department of Pathology, National Cancer Center/National Clinical Research Center
36 for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union
37 Medical College, Beijing 100021, China
38
39

40
41 *Hongda Chen and Ni Li contributed equally to this work.

42 **Address for Correspondence:** Prof. Min Dai, PhD, National Cancer Center/National
43 Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical
44 Sciences and Peking Union Medical College, Beijing 100021, China; Email:
45 daimin2002@hotmail.com; Tel: +86-10-8778-7394
46
47
48
49

50 **Word account:**3820
51
52
53
54
55
56
57
58
59
60

1 **Abstract**

2 **Introduction:** Screening for colorectal cancer (CRC) has been demonstrated to be
3 effective in reducing the burden of the disease. However, high-level evidence from
4 randomized controlled trials on the effectiveness of CRC screening modalities is still
5 lacking. We will conduct a large-scale multi-center randomized controlled trial for
6 CRC screening in China to evaluate the effectiveness and cost-effectiveness of
7 different CRC screening strategies.

8 **Methods and analysis:** 20,000 eligible participants aged 50-74 years are enrolled in five
9 provinces in China. After providing signed informed consent, the participants will be
10 randomized into one of the three screening groups: 1) one-time colonoscopy (N=4,000);
11 2) annual fecal immunochemical test (FIT) (N=8,000); 3) annual risk-adapted screening
12 strategy (N=8,000). For the risk adapted screening strategy, an established colorectal
13 cancer risk scoring system, the Asia-Pacific Colorectal Screening (APCS) score, will
14 be used. Participants at high-risk of CRC will be referred to colonoscopy and
15 participants at low-risk of CRC will be referred to take a FIT. Information on clinical
16 reports, epidemiological risk factors and health economic factors will be collected and
17 stored in a web-based data management system. We further request the participants to
18 donate blood, fecal and saliva samples before conducting colonoscopy. The primary
19 outcome is the detection rate of advanced colorectal neoplasia, and the secondary
20 outcomes include the CRC-related mortality rate, incidence rate of CRC, participation
21 rate and complication rate. The study will last for at least four years and the cohort will

1
2
3
4 1 be followed for ten years to adequately answer the scientific questions.
5
6
7

8 2 **Ethics and dissemination:** This study was approved by the Ethics Committee of the
9
10 3 National Cancer Center/Cancer Hospital, the Chinese Academy of Medical Sciences
11
12 4 and the Peking Union Medical College (18-013/1615). The results of the study will be
13
14 5 submitted for publication in peer-reviewed journals and will be discussed by policy and
15
16 6 decision makers.
17
18
19

20
21 7 **Trial registration:** Chinese Clinical Trial Registry (ChiCTR1800015506,
22
23 8 prospectively registered on 3 April 2018).
24
25

26 9 **Keywords:** Colorectal cancer, Early detection, Risk score, Advanced adenoma;
27
28
29 10 Randomized controlled trial
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- This is the first large-scale population-based colorectal cancer screening trial to compare the effectiveness and cost-effectiveness of three different screening strategies targeting adults aged 50 to 74 years old in China.
- A comprehensive health-economic evaluation will be performed to evaluate the cost-effectiveness of different screening arms and policy advice will therefore be provided based on the study findings.
- Prospective biospecimens collected before screening colonoscopy will be a valuable resource to explore novel biomarkers for early detection of colorectal cancer in further research.
- The sample sizes of the study population may not be adequate to compare the mortality reduction among the three screening arms after long-term follow-up.

1 **Introduction**

2 Colorectal Cancer (CRC) is the third most commonly diagnosed cancer and the second
3 most common cause of cancer-related death worldwide [1]. In China, with an estimate
4 of 376,300 newly diagnosed CRC cases and 191,000 CRC-related deaths in 2015, the
5 incidence ranked fourth and mortality ranked fifth of all cancer types. Notably, the
6 incidence and mortality of CRC has been steadily increasing over the past decades in
7 China [2]. Therefore, establishment of strategies on curbing the rising momentum of
8 CRC in China is strongly required.

9 Evidence from randomized controlled trials and observational studies have
10 demonstrated that screening could reduce the burden of CRC [3-5]. The established
11 screening modalities include colonoscopy, flexible sigmoidoscopy, and stool-based
12 tests (such as the fecal occult blood test (FOBT)), which have been widely used in many
13 screening programs worldwide [6-8]. Colonoscopy is the gold standard for CRC.
14 However, in population-based screening programs, colonoscopy is limited by low
15 compliance rate, potential complication, high cost and limited resources [9, 10].
16 Guaiac-based FOBT (gFOBT) was introduced in the 1980s. Although the sensitivity of
17 gFOBT for detecting CRC is not optimal, randomized controlled trials demonstrated
18 that screening by gFOBT yielded a reduction in CRC mortality [5]. To date, the newly
19 developed fecal immunochemical test (FIT) for hemoglobin showed superior
20 diagnostic performance than traditional gFOBT [11]. However, evidence from
21 randomized controlled trials to evaluate the screening efficacy of FIT is still lacking,

1 especially in the Chinese population [11].

2 Current guidelines recommend CRC screening for average-risk adults at a starting age
3 of 50 years old [12-15]. However, in countries with unbalanced and limited healthcare
4 resources, identification of high-risk populations and the development of risk-adapted
5 screening strategies would be potentially more cost-efficient than traditional screening
6 strategies. In previous studies, CRC risk scores based on environmental and/or generic
7 factors were developed, which typically presented moderate diagnostic efficacy [16].
8 Further combining risk scores with established screening modalities such as colonoscopy
9 and FIT was proposed and has shown promising diagnostic performance [13, 17, 18].
10 However, further validation of such risk-adapted screening strategies in large
11 prospective cohorts and randomized controlled trial are still sparse.

12 Searching for biomarkers in early detection of CRC is a promising research area.
13 Different types of biomarkers, including blood proteins, blood DNA methylation, fecal
14 DNA, fecal microbiota and oral microbiota, were reported to be associated with CRC
15 and could be potential targets for early detection of CRC [19]. Using the ongoing
16 screening trials to construct the biobank will be both time- and economic- saving, which
17 will also be an important platform for biomarker identification and validation for further
18 investigations.

19 In China, screening for CRC has been implemented in several regions over the past
20 decades [20, 21]. However, high-quality evidence of recommendation of CRC
21 screening in the Chinese population is still lacking and in high demand [20]. Therefore,

1 we planned to conduct a population-based, multicenter, randomized controlled trial
2 comparing colonoscopy, FIT and a novel risk-adapted screening strategy for CRC
3 screening in the Chinese population, with the following aims: 1) to establish a large-
4 scale CRC screening cohort with long-term follow-ups in China; 2) to evaluate the
5 effectiveness and cost-effectiveness of different CRC screening strategies in the
6 Chinese population; 3) to construct a large epidemiological and clinical database and a
7 biobank for further studies.

1 **Methods/Design**

2 ***Study setting and design***

3 This is a prospective, multicenter, randomized controlled trial comparing multiple
4 screening strategies on CRC screening in China. Participants who meet the study
5 inclusion and exclusion criteria are recruited in five provinces in China. We aim to
6 recruit at least 20,000 eligible participants at baseline. After obtaining signed informed
7 consent, eligible participants are randomly allocated into one of the following three
8 CRC screening groups in a 1:2:2 ratio (Figure 1). A four-year screening phase (with
9 one-year baseline screening and three years follow-up screening) will be conducted
10 for all participants, and a subsequent passive follow-up phase will also be implemented
11 until the scientific questions are answered adequately. Detailed information about
12 follow-up is shown in the following section.

13 1) ***Colonoscopy group (N=4,000)***: participants are recommended to undertake one-
14 time screening colonoscopy at baseline. Abnormal findings removed during
15 colonoscopy will be sent to pathology for further analysis. . For the following
16 years, all the participants will be interviewed to complete the follow-up
17 questionnaire annually.

18 2) ***FIT group (N=8,000)***: FITs are offered to the participants annually. Participants
19 who have positive FIT results are recommended to have a diagnostic
20 colonoscopy. Abnormal findings removed during colonoscopy will be sent to
21 pathology for further analysis.

1
2
3
4 1) **Risk assessment group (N=8,000):** Colorectal cancer risk will be assessed using
5
6 an established CRC risk stratification scoring system at baseline. For participants
7
8 with high risk of CRC, screening colonoscopy will be offered. For participants
9
10 with low risk of CRC, FITs are offered and those with positive FIT results are
11
12 recommended to take further colonoscopy. During the annual follow-ups,
13
14 participants who have negative FIT results and participants who have not had a
15
16 screening colonoscopy will complete another round of risk assessment and the
17
18 same screening procedures as at baseline will be offered. For participants who
19
20 have already undertaken screening colonoscopy, no further screening intervention
21
22 will be provided but will complete a questionnaire annually during the study
23
24 period.
25
26
27
28
29
30
31
32

33 **Randomization and allocation procedure**

34
35 The randomization is conducted in a centralized controlled manner. The leading
36
37 institute (Cancer Hospital, Chinese Academy of Medical Sciences) is responsible for
38
39 the generation of the randomization scheme using a predefined seed by the statistical
40
41 software R. Before recruitment, the staff who are responsible for the recruitment at
42
43 each site and the participants are blinded to the allocation results. The allocation results
44
45 are revealed after successful registration of the subject in a web-based data system. At
46
47 the time of randomization, a unique Study Identification Number (SIN) is allocated to
48
49 the participant and will be used for the participants during the entire study period.
50
51
52
53
54
55
56
57

58 **Study population and recruitment**

59
60 Participants aged 50 to 74 years who live in the study region and are able to sign

1 informed consent are eligible for this study. Exclusion criteria are: 1) prior history of
2 colorectal cancer; 2) prior history of colonic resection; 3) undertaking any kind of
3 cancer related therapy (except for non-melanoma skin cancer); 4) prior colonic
4 examination, including colonoscopy, flexible sigmoidoscopy, CT colonography and
5 Barium enema within five years; 5) prior history of fecal occult blood test and fecal
6 DNA test within 1 year; 6) symptoms of lower gastrointestinal tract disease warranting
7 colonoscopic evaluation, including: a) more than one episode of rectal bleeding within
8 the past 6 months; b) documented iron deficiency anemia; c) significant documented
9 unintentional weight loss (>10% of baseline weight) over 6 months; 7) significant
10 comorbidity that would preclude benefit from screening or pose significant risk for the
11 performance of colonoscopy (e.g. severe lung disease, end-stage renal disease, end-
12 stage liver disease, severe heart failure, recent diagnosis of cancer (with the exception
13 of non-melanoma skin cancer).

14 Recruitment procedures will involve the following steps:

- 15 (1) Recruitment of potential participants aged 50 to 74 years in the selected
16 communities and check for eligibility by trained study staff;
- 17 (2) Signed written informed consent obtained from the eligible participants by
18 trained study staff;
- 19 (3) Registration of the participant in the web-based data management system, SIN
20 allocated, and randomization results revealed;
- 21 (4) Conducting respective intervention strategies per protocol;

1
2
3
4 **1 *Interventions***

5
6 **2 *Colonoscopy***

7
8
9 3 Standard clinical procedures of the screening colonoscopy will be followed, including
10
11 4 appointment, obtaining informed consent, routine blood test for infectious diseases
12
13 5 including hepatitis B virus (HBV), hepatitis C virus (HCV) and human
14
15 6 immunodeficiency virus (HIV) infections (if required by the hospitals, otherwise not
16
17 7 implemented), distribution of bowel preparation drugs, diet control, anesthesia (if
18
19 8 required by the participants) and colonoscopy examination. Colonoscopy will be
20
21 9 performed by experienced endoscopists who have more than five-year experience
22
23 10 performing colonoscopy. Abnormal findings during colonoscopy are carefully checked
24
25 11 under standard clinical procedures and tissue specimens are collected for further
26
27 12 pathology diagnosis. Any findings during colonoscopy are required to be photo
28
29 13 documented. Clinical information such as the examination duration, sedation status,
30
31 14 completeness, bowel preparation status, complication, polyp features (such as number,
32
33 15 position, size, color and shape), description of other abnormal findings, as well as
34
35 16 pathology diagnosis will be collected and documented in the web-based data
36
37 17 management system.
38
39
40
41
42
43
44
45
46
47
48

49 18 For quality control, an expert panel including experienced endoscopists and
50
51 19 pathologists will be formed. Each year, a selection of colonoscopy and pathology
52
53 20 documentation will be assessed by the expert panel, and review reports will be
54
55 21 transferred to the respective physicians about their performance.
56
57
58
59
60

1 *Fecal immunochemical test (FIT)*

2 Fecal immunochemical tests for human hemoglobin are provided by the study staff to
3 participants after successful registration in this study. The FIT used in this study is a
4 self-administered qualitative test, providing an endpoint that is read as positive or
5 negative by eye if the fecal hemoglobin concentration exceeds the manufacturer-
6 specific threshold. The participants can submit the results to the study website along
7 with the picture of the test window or will be interviewed by the study staff for the test
8 results within three days of distributing the FIT. For participants having invalid test
9 results, new test devices will be provided until a valid test result is available.
10 Participants are contacted and a follow up colonoscopy will be arranged if they are
11 confirmed to have positive FIT results.

12 *Colorectal cancer risk assessment*

13 In this study, an established colorectal cancer risk scoring system, the Asia-Pacific
14 Colorectal Screening (APCS) score [22, 23], will be used. The APCS score is derived
15 based on five common risk factors of CRC, including age, sex, family history of CRC
16 in a first-degree relative, smoking and BMI (Body Mass Index). In a previous study
17 conducted in Hong Kong, the subjects of high-risk defined by the APCS score had 2.48-
18 fold increased prevalence of advanced neoplasm than the low-risk subjects, with the c-
19 statistics of 0.65. Detailed information of the APCS score used in our study is shown
20 in Table 1. Generally, for the risk-adapted screening group, participants are asked to
21 filled in a questionnaire including the above mentioned risk factors. Participants with a
22 score ≥ 4 are defined to be at high-risk of CRC, and participants with a score < 4 are

1 defined to have a low-risk of CRC. Participants will be informed about their
2 evaluation results and receive the respective screening intervention as per the study
3 protocol.

4 ***Patient and Public Involvement***

5 During the process of recruitment, the participants will be informed about the research
6 question, study design and screening intervention by study staff. The participants can
7 quit the study and withdrawn the informed consent at any time based on their priorities,
8 experiences or preferences. The participant and public had no role in the study design,
9 recruitment and conduct of the study. All the screening intervention will be provided to
10 the participants at no cost (compensated by this study), except for the subsequent
11 therapeutic costs which must be paid by the participants themselves. The burden of the
12 intervention and potential subsequent therapeutic procedure will be informed by the
13 study staff at the recruitment phase. A report summarizing the screening results will be
14 disseminated to the participants by study staff.

16 ***Biospecimen collection and handling***

17 Participants who need to undertake colonoscopy are invited to donate stool, saliva and
18 blood samples prior to colonoscopy. Standard Operating Procedures (SOPs) regarding
19 biospecimen collection, handling and storage have been formulated and will be
20 followed.

21 For stool samples, collection devices (including sample collection vials, ice bags,
22 isothermal bags and operation brochures) are distributed. At the day before

1
2
3
4 1 colonoscopy, participants are suggested to collect raw stool samples before taking
5
6 2 bowel cleaning drugs for colonoscopy. The participants are recommended to store the
7
8
9 3 samples in the freezer or in the isothermal bags with ice bags until transported to the
10
11 4 hospital. The samples are stored in the freezer (-80°C) immediately for future use when
12
13
14 5 received.

15
16
17
18 6 For saliva samples, participants are provided with sample collection tubes (with oral
19
20 7 DNA stabilization buffer) during their visit to the hospital before colonoscopy. Study
21
22
23 8 staff will guide the participants for the saliva sample collection procedure. Collected
24
25
26 9 samples will be aliquoted immediately and stored in the freezer (-80°C) for future use.

27
28
29
30 10 For blood samples, around 10ml vein blood samples (including 5ml EDTA
31
32 11 anticoagulated blood and 5ml non-anticoagulation blood) will be drawn from the
33
34
35 12 participants during their visit to the hospital before colonoscopy. Under the SOPs, blood
36
37
38 13 samples are centrifuged, aliquoted and then stored in the freezer (-80°C) for future use.

39
40
41 14 ***Follow up***

42
43 15 Both active follow-up and passive follow-up will be conducted in this study. For the
44
45
46 16 active follow-up, all the participants will be interviewed by trained study staff by
47
48
49 17 telephone call, home visit or other contact methods for collection of information such
50
51
52 18 as physical examination, health status and outcome. For the passive follow-up, linkage
53
54
55 19 data from cancer registry system, death surveillance system, medical insurance and
56
57
58 20 claim database will be used to track the outcome of the participants.

1 **Contamination evaluation**

2 During the study period, the study team will contact the participants to evaluate the
3 status of CRC beyond the study protocol. The extra screening examinations conducted
4 by the participant during the study period are not allocated by the randomization, and
5 therefore may introduce contamination to the study results. To evaluate the
6 contamination status of this study, all participants who are screened to have negative
7 findings will complete one round of questionnaire interview in the fourth year of the
8 study. Information regarding the history of diagnostic or screening colonic examination
9 will be collected and assessed. We anticipate controlling the contamination rate to be
10 below 10%. For the final analysis report, the contamination will be taken into
11 consideration to estimate the screening effects.

12 **Outcome measures**

13 The primary outcome is the colorectal cancer mortality rate . The secondary outcomes
14 include detection rate of CRC, detection rate of precancerous lesions of CRC,
15 compliance rate, complication rate.

16 **Data collection**

17 *Epidemiological risk factor investigation*

18 A standardized epidemiological questionnaire will be administered by trained
19 interviewers to all participants to investigate the risk factors of colorectal cancer.
20 Information including sociodemographic factors, history of bowel disease and clinical
21 treatment, living habits, disease history and family history of cancer are collected and
22 stored in the web-based data management system.

1
2
3 1 *Health economic information*
4

5 2 Comprehensive health economic evaluation will be conducted. Questionnaires
6
7
8 3 including the EuroQol five dimensions questionnaire (EQ-5D) and EQ-5D-5L will be
9
10 4 used to measure the health state of the participants. The direct costs on materials,
11
12
13 5 equipment, personnel, drug and other resources will be collected from all participating
14
15
16 6 sites to estimate the cost-effectiveness of different screening strategies in this clinical
17
18 7 trial.
19

20
21
22 8 **Data monitoring committee**
23

24 9 A data monitoring committee composed of epidemiologists, endoscopists,
25
26
27 10 pathologists and colorectal surgeons will monitor the data collection process and
28
29
30 11 analyses. All data will be transmitted to the Central Data Management Team in the
31
32 12 National Cancer Center of China/Cancer Hospital Chinese Academy of Medical
33
34
35 13 Sciences, where the databases are constructed, and analyses are performed. In addition,
36
37 14 any adverse events (e.g., perforation, bleeding) will be recorded in standardized forms
38
39
40 15 by the study sites and will also be reported to the Ethics Committee for record.
41

42
43 16 **Statistical Considerations**
44

45
46 17 *Sample size*
47

48 18 Sample sizes were calculated based on the evaluation of primary outcomes, i.e.,
49
50
51 19 advanced neoplasia detection rate. The hypothesis was that the advanced neoplasia
52
53
54 20 detection rate of the risk-adapted screening group was superior to the FIT group and
55
56
57 21 non-inferior to the colonoscopy group. According to previous studies, the advanced
58
59 22 neoplasia detection rate of colonoscopy, FIT and risk-adapted screening groups were
60

1 6.5%, 1.8% and 5.0% respectively [13, 24]. We assumed the compliance rate was 50%
2 to 70% for colonoscopy, 60%-90% for FIT and 60%-90% for the risk-adapted screening
3 strategy and an overall loss-to-follow-up of 10%. For the comparison between the risk-
4 adapted screening strategy group and the FIT group at different scenarios of the
5 compliance rates, the largest sample size needed was 6550 when we set the significance
6 level of $\alpha=0.05$, the power of 0.8 and superiority margin (δ) of -0.005. For the
7 comparison between the risk-adapted screening group and the colonoscopy group,
8 when assuming the respective compliance rates were 85% and 60%, the required
9 sample sizes were 6032 and 3016, respectively, when we set the significance level of
10 $\alpha=0.05$, the power of 0.8, non-inferiority margin (δ) of -0.001. Therefore, the sample
11 sizes of this study design (4000 for the colonoscopy group, 8000 for the FIT group and
12 8000 for the risk-adapted screening group) will accomplish the study hypotheses.

13 **Statistical analyses**

14 The primary outcome analysis will be a comparison of histologically confirmed CRC
15 and advanced adenoma between the three intervention arms taking into consideration
16 the compliance rate. Intention-to-treat and per-protocol analyses will be conducted. For
17 secondary outcomes, mortality rate will be calculated as the ratio of the number of
18 deaths due to CRC to the person-years at risk for each group. Person-years will be
19 estimated from the time of randomization to the diagnosis date of CRC, death or
20 censoring at the end of the study. The incidence rate will be estimated in a similar way.
21 Chi-square tests and t-tests are used to compare categorical and continuous variables
22 between the two groups, respectively. The Cox proportional hazards regression model

1
2
3
4 1 is adopted to examine the difference of incidence and mortality between different
5
6 2 screening groups. For health economic evaluation, Markov models will be developed
7
8
9 3 to evaluate the cost-effectiveness of different screening strategies for CRC in China.
10
11 4 Statistical software, such as SAS software (version 9.2; SAS Institute, Cary, NC, USA),
12
13
14 5 R (version 3.4.1, R Foundation for Statistical Computing, Vienna, Austria) and
15
16
17 6 TreeAge Pro 2016 (TreeAge Software, Inc., MA, USA), will be used in the data
18
19
20 7 analyses.
21
22
23
24

8

9 ***Ethics and dissemination***

10 This study was approved by Ethics Committee of the National Cancer Center/Cancer
11 Hospital, the Chinese Academy of Medical Sciences and the Peking Union Medical
12 College (approved number:18-013/1615) and the protocol was registered in the Chinese
13 Clinical Trial Registry (registration number: ChiCTR1800015506).
14
15
16
17
18

14 The results of the study will be submitted for publication to peer-reviewed journals and
15 conferences following the Consolidated Standards of Reporting Trials guidelines. The
16 results will be discussed by policy and decision makers. Access to the detailed research
17 plan, participant-level dataset and statistical analysis code will be granted based on
18 reasonable requests after the publication of the study.
19
20
21
22

19 ***Trial status***

20 This screening trial is currently in the participant enrolment phase. 1600 eligible
21 participants have been randomized and are under respective colorectal cancer screening
22 as of August 2018. We anticipate the full analysis to be finalized in December 2021.

1 Discussion

2 Our study aims to evaluate the effectiveness and cost-effectiveness of three strategies
3 for CRC screening in China. To our knowledge, this is the first large-scale randomized
4 controlled trial on CRC screening based on a community population in China.
5 Colonoscopy is the gold standard for CRC screening, and FIT is the most widely used
6 non-invasive CRC screening test. However, the magnitude of the effect of colonoscopy
7 and FIT in population-based CRC screening is uncertain due to lack of evidence from
8 randomized controlled trials. To date, there are three large-scale randomized controlled
9 trials (SCREESCO, CONFIRM and COLONPREV) comparing colonoscopy or FIT
10 screening with regard to CRC incidence and mortality [25-28]. All the three trials are
11 currently ongoing and conducted in Europe and North America. Our study will be the
12 first large-scale CRC screening trial in Asia. In addition, we also include a novel risk-
13 adapted screening strategy in our trial, which incorporates risk assessment with
14 established screening methods. Our study will provide strong evidence on the
15 effectiveness and feasibility of different strategies for CRC screening in China.

16 In recent years, the burden of CRC has been increasing in East-Asia which has been
17 explained by changes in diet and a westernized lifestyle [29]. Countries including China,
18 Japan and South Korea have implemented organized screening programs. For instance,
19 in Japan, the CRC screening program initiated in 1992, uses FIT as the main screening
20 method and the cost is covered by the national health insurance [30]. In China,
21 individuals aged 40-74 years are screened with FOBT or colonoscopy based on clinical

1 risk indexes in some regions but not the entire country [20]. Furthermore, the most
2 appropriate techniques for different populations in China are still under debate. The
3 results of our study will therefore provide high-level evidence to design CRC screening
4 strategy for China and provides essential references for other countries.

5 In this study, we plan to finish the baseline recruitment and baseline screening before
6 June of 2019 and will continue to have a total of three rounds of the screening
7 intervention FIT group and the risk-adapted screening group. Long term passive follow-
8 up will also be conducted to obtain the health outcomes of the participants and will be
9 used for evaluation of the long-term effect of CRC screening. There are several
10 strengths of our study. Firstly, we use a prospective randomized design which would
11 minimize the selection bias and provide high-level evidence compared to other study
12 designs such as cross-sectional studies. In addition, except for active follow-ups, we
13 will also implement passive follow-ups using multiple resources such as cancer registry,
14 death surveillance system, medical insurance and claim databases to track the outcomes
15 of all the study participants. We will also construct a large biobank using prospectively
16 collected specimens. Such a biobank will serve as an essential platform for biomarker
17 identification and validation for further investigations.

18 The major challenges of this study are the control of loss to follow-up and the quality
19 control of a multi-center project. To address such concern, we will employ experienced
20 study staff to contact and visit the participants regularly. Moreover, a health education
21 campaign will be conducted to improve the health literacy by means of lectures, videos,

1 advertisement and social media. For the quality control, we will build an expert panel
2 including experts of epidemiologists, endoscopists, pathologists and surgeons. A
3 capacity training workshop will be held annually, and a selection of study reports will
4 be reviewed to ensure the study quality.

5 To sum up, this is a large-scale multi-center randomized controlled trial, comparing
6 three strategies for CRC screening. Successful implementation of this study will
7 provide strong evidence on the effectiveness and cost-effectiveness of CRC screening
8 and provide essential references for policy-makers to design national screening
9 programs in the future.

1 **Authors' contributions**

2 HC, NL and MD designed the study protocol, HC and NL drafted the manuscript, JS,
3 JR, CL, YZ, ZJ, ZZ and MD critically reviewed and revised the manuscript. All authors
4 read and approved the final manuscript.

5 **Funding statement:**

6 This study was sponsored by CAMS Innovation Fund for Medical Sciences (2017-I2M-
7 1-006) and National Natural Science Foundation of China (81703309). The funder had
8 no role in the design and conduct of the study; collection, management, analysis, and
9 interpretation of the data; preparation, review, or approval of the manuscript; and
10 decision to submit the manuscript for publication.

11 **Competing interests**

12 The authors declare that they have no competing interests.

13 **Acknowledgements**

14 The authors would like to thank all participating sites: Zhejiang Cancer Hospital, Anhui
15 Provincial Cancer Hospital, Xuzhou Cancer Hospital, Hunan Cancer Hospital Yunnan
16 Cancer Hospital, Center for Disease Control and Prevention of the participating cities,
17 the community staff and participants for their contribution. We also thank Dr. Prudence
18 Carr for the English proof reading of this manuscript.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, and Jemal A, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*, 2018. 68(6): 394-424.
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, and He J, Cancer statistics in China, 2015. *CA Cancer J Clin*, 2016. 66(2): 115-32.
3. Zorzi M, Fedeli U, Schievano E, Bovo E, Guzzinati S, Baracco S, Fedato C, Saugo M, and Dei Tos AP, Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test. *Gut*, 2015. 64(5): 784-90.
4. Brenner H, Stock C, and Hoffmeister M, Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. *Bmj*, 2014. 348: g2467.
5. Hewitson P, Glasziou P, Watson E, Towler B, and Irwig L, Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. *Am J Gastroenterol*, 2008. 103(6): 1541-9.
6. Brenner H, Kloor M, and Pox CP, Colorectal cancer. *Lancet*, 2014. 383(9927): 1490-502.
7. Schreuders EH, Ruco A, Rabeneck L, Schoen RE, Sung JJ, Young GP, and Kuipers EJ, Colorectal cancer screening: a global overview of existing programmes. *Gut*, 2015. 64(10): 1637-49.
8. Whitlock EP, Lin JS, Liles E, Beil TL, and Fu R, Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. *Ann Intern Med*, 2008. 149(9): 638-58.
9. Senore C, Inadomi J, Segnan N, Bellisario C, and Hassan C, Optimising colorectal cancer screening acceptance: a review. *Gut*, 2015. 64(7): 1158-77.
10. Robertson DJ, Kaminski MF, and Bretthauer M, Effectiveness, training and quality assurance of colonoscopy screening for colorectal cancer. *Gut*, 2015. 64(6): 982-90.
11. Tinmouth J, Lansdorp-Vogelaar I, and Allison JE, Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know. *Gut*, 2015. 64(8): 1327-37.
12. Lin JS, Piper MA, Perdue LA, Rutter CM, Webber EM, O'Connor E, Smith N, and Whitlock EP, Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *Jama*, 2016. 315(23): 2576-94.
13. Chiu HM, Ching JY, Wu KC, Rerknimitr R, Li J, Wu DC, Goh KL, Matsuda T, Kim HS, Leong R, Yeoh KG, Chong VH, Sollano JD, Ahmed F, Menon J, and Sung JJ, A Risk-Scoring System Combined With a Fecal Immunochemical Test Is Effective in Screening High-Risk Subjects for Early Colonoscopy to Detect Advanced Colorectal Neoplasms. *Gastroenterology*, 2016. 150(3): 617-25.e3.
14. Provenzale D, Jasperson K, Ahnen DJ, Aslanian H, Bray T, Cannon JA, David DS, Erwin D, Ford JM, Giardiello FM, Gupta S, Halverson AL, Hamilton SR, Hampel H, Ismail MK, Klapman JB, Larson DW, Lazenby AJ, Lynch PM, Mayer RJ, Ness RM, Rao MS, Regenbogen SE, Shike M, Steinbach G, Weinberg D, Dwyer MA, Freedman-Cass DA, and Darlow S, Colorectal Cancer Screening, Version 1.2015. *J Natl Compr Canc Netw*, 2015. 13(8): 959-68; quiz 68.
15. Armaroli P, Villain P, Suonio E, Almonte M, Anttila A, Atkin WS, Dean PB, de Koning HJ, Dillner L, Herrero R, Kuipers EJ, Lansdorp-Vogelaar I, Minozzi S, Paci E, Regula J, Tornberg S, and

- 1
2
3 Segnan N, European Code against Cancer, 4th Edition: Cancer screening. *Cancer Epidemiol*,
4 2015. 39 Suppl 1: S139-52.
- 5
6 16. Win AK, Macinnis RJ, Hopper JL, and Jenkins MA, Risk prediction models for colorectal cancer:
7 a review. *Cancer Epidemiol Biomarkers Prev*, 2012. 21(3): 398-410.
- 8
9 17. Jung YS, Park CH, Kim NH, Park JH, Park DI, and Sohn CI, A combination of clinical risk
10 stratification and fecal immunochemical test is useful for identifying persons with high priority
11 of early colonoscopy. *Dig Liver Dis*, 2018. 50(3): 254-59.
- 12
13 18. Cubiella J, Digby J, Rodriguez-Alonso L, Vega P, Salve M, Diaz-Ondina M, Strachan JA, Mowat
14 C, McDonald PJ, Carey FA, Godber IM, Younes HB, Rodriguez-Moranta F, Quintero E, Alvarez-
15 Sanchez V, Fernandez-Banares F, Boadas J, Campo R, Bujanda L, Garayoa A, Ferrandez A, Pinol
16 V, Rodriguez-Alcalde D, Guardiola J, Steele RJ, and Fraser CG, The fecal hemoglobin
17 concentration, age and sex test score: Development and external validation of a simple
18 prediction tool for colorectal cancer detection in symptomatic patients. *Int J Cancer*, 2017.
19 140(10): 2201-11.
- 20
21 19. Dickinson BT, Kisiel J, Ahlquist DA, and Grady WM, Molecular markers for colorectal cancer
22 screening. *Gut*, 2015. 64(9): 1485-94.
- 23
24 20. Goss PE, Strasser-Weippl K, Lee-Bychkovsky BL, Fan L, Li J, Chavarri-Guerra Y, Liedke PE,
25 Pramesh CS, Badovinac-Crnjevic T, Sheikine Y, Chen Z, Qiao YL, Shao Z, Wu YL, Fan D, Chow
26 LW, Wang J, Zhang Q, Yu S, Shen G, He J, Purushotham A, Sullivan R, Badwe R, Banavali SD,
27 Nair R, Kumar L, Parikh P, Subramanian S, Chaturvedi P, Iyer S, Shastri SS, Digumarti R, Soto-
28 Perez-de-Celis E, Adilbay D, Semiglazov V, Orlov S, Kaidarova D, Tsimafeyeu I, Tatishchev S,
29 Danishevskiy KD, Hurlbert M, Vail C, St Louis J, and Chan A, Challenges to effective cancer
30 control in China, India, and Russia. *Lancet Oncol*, 2014. 15(5): 489-538.
- 31
32 21. Guo C, Liu Q, and Dai M, [Colorectal cancer screening: situation and prospect]. *Zhonghua Yu*
33 *Fang Yi Xue Za Zhi*, 2015. 49(5): 377-80.
- 34
35 22. Sung JY, Wong MCS, Lam TYT, Tsoi KKF, Chan VCW, Cheung W, and Ching JYL, A modified
36 colorectal screening score for prediction of advanced neoplasia: A prospective study of 5744
37 subjects. *J Gastroenterol Hepatol*, 2018. 33(1): 187-94.
- 38
39 23. Yeoh KG, Ho KY, Chiu HM, Zhu F, Ching JY, Wu DC, Matsuda T, Byeon JS, Lee SK, Goh KL, Sollano
40 J, Rerknimitr R, Leong R, Tsoi K, Lin JT, and Sung JJ, The Asia-Pacific Colorectal Screening score:
41 a validated tool that stratifies risk for colorectal advanced neoplasia in asymptomatic Asian
42 subjects. *Gut*, 2011. 60(9): 1236-41.
- 43
44 24. Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, Ahlquist DA, and Berger
45 BM, Multitarget stool DNA testing for colorectal-cancer screening. *N Engl J Med*, 2014. 370(14):
46 1287-97.
- 47
48 25. Kaminski MF, Bretthauer M, Zauber AG, Kuipers EJ, Adami HO, van Ballegooijen M, Regula J,
49 van Leerdam M, Stefansson T, Pahlman L, Dekker E, Hernan MA, Garborg K, and Hoff G, The
50 NordICC Study: rationale and design of a randomized trial on colonoscopy screening for
51 colorectal cancer. *Endoscopy*, 2012. 44(7): 695-702.
- 52
53 26. Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanás A, Andreu M, Carballo F, Morillas
54 JD, Hernandez C, Jover R, Montalvo I, Arenas J, Laredo E, Hernandez V, Iglesias F, Cid E,
55 Zubizarreta R, Sala T, Ponce M, Andres M, Teruel G, Peris A, Roncales MP, Polo-Tomas M, Bessa
56 X, Ferrer-Armengou O, Grau J, Serradesanferm A, Ono A, Cruzado J, Perez-Riquelme F, Alonso-
57 Abreu I, de la Vega-Prieto M, Reyes-Melian JM, Cacho G, Diaz-Tasende J, Herreros-de-Tejada
58
59
60

- 1
2
3 A, Poves C, Santander C, and Gonzalez-Navarro A, Colonoscopy versus fecal immunochemical
4 testing in colorectal-cancer screening. N Engl J Med, 2012. 366(8): 697-706.
5
6 27. CONFRIM trial at <http://www.clinicaltrials.gov/ct2/show/NCT01239082> (accessed 28 April
7 2018).
8
9 28. Screesco trial at <http://www.clinicaltrials.gov/ct2/show/NCT02078804> (accessed 28 April
10 2018).
11
12 29. Sung JJ, Lau JY, Goh KL, and Leung WK, Increasing incidence of colorectal cancer in Asia:
13 implications for screening. Lancet Oncol, 2005. 6(11): 871-6.
14
15 30. Saito H, Colorectal cancer screening using immunochemical faecal occult blood testing in Japan.
16 J Med Screen, 2006. 13 Suppl 1: S6-7.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Risk factors and respective advocated points of the Asia-Pacific Colorectal Screening (APCS) score used in this trial

Risk factor	Criteria	Points
Age (years)	<50	0
	50-69	1
	≥70	2
Sex	Female	0
	Male	1
Family history of colorectal cancer in a first-degree relative	Absent	0
	Present	1
Smoking	No	0
	Current or past	1
BMI	<23	0
	≥23	1

Abbreviations: BMI, Body Mass Index, calculated as Weight (kg)/height²(meter²)

Figure Legend

Figure 1. SPIRIT flow diagram of the study design

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. SPIRIT flow diagram of the study design

338x190mm (133 x 120 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Page
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	4
	2b	All items from the World Health Organization Trial Registration Data Set	4
Protocol version	3	Date and version identifier	NA
Funding	4	Sources and types of financial, material, and other support	22
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	22
	5b	Name and contact information for the trial sponsor	NA
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	22
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	11
Introduction			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	5
	6b	Explanation for choice of comparators	5 and 6
Objectives	7	Specific objectives or hypotheses	5 and 6
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	7

Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	8
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	10
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	8 and 9
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	10
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	10
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	11
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	14
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	8
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	15
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	10

Methods: Assignment of interventions (for controlled trials)

Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	9
---------------------	-----	--	---

1	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central	9
2	concealment		telephone; sequentially numbered, opaque, sealed envelopes),	
3	mechanism		describing any steps to conceal the sequence until interventions are	
4			assigned	
5				
6				
7	Implementation	16c	Who will generate the allocation sequence, who will enrol participants,	9
8			and who will assign participants to interventions	
9				
10	Blinding	17a	Who will be blinded after assignment to interventions (eg, trial	9
11	(masking)		participants, care providers, outcome assessors, data analysts), and	
12			how	
13				
14		17b	If blinded, circumstances under which unblinding is permissible, and	9
15			procedure for revealing a participant's allocated intervention during	
16			the trial	
17				

18 **Methods: Data collection, management, and analysis**

19				
20	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other	15
21	methods		trial data, including any related processes to promote data quality (eg,	
22			duplicate measurements, training of assessors) and a description of	
23			study instruments (eg, questionnaires, laboratory tests) along with	
24			their reliability and validity, if known. Reference to where data	
25			collection forms can be found, if not in the protocol	
26				
27				
28		18b	Plans to promote participant retention and complete follow-up,	13
29			including list of any outcome data to be collected for participants who	
30			discontinue or deviate from intervention protocols	
31				
32	Data	19	Plans for data entry, coding, security, and storage, including any	15
33	management		related processes to promote data quality (eg, double data entry;	
34			range checks for data values). Reference to where details of data	
35			management procedures can be found, if not in the protocol	
36				
37	Statistical	20a	Statistical methods for analysing primary and secondary outcomes.	16
38	methods		Reference to where other details of the statistical analysis plan can be	
39			found, if not in the protocol	
40				
41		20b	Methods for any additional analyses (eg, subgroup and adjusted	16
42			analyses)	
43				
44		20c	Definition of analysis population relating to protocol non-adherence	16
45			(eg, as randomised analysis), and any statistical methods to handle	
46			missing data (eg, multiple imputation)	
47				
48				

49 **Methods: Monitoring**

50				
51	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role	11
52			and reporting structure; statement of whether it is independent from	
53			the sponsor and competing interests; and reference to where further	
54			details about its charter can be found, if not in the protocol.	
55			Alternatively, an explanation of why a DMC is not needed	
56				
57				
58				
59				
60				

1		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	NA
2				
3				
4				
5				
6	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	15
7				
8				
9				
10	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	NA
11				
12				
13				
14	Ethics and dissemination			
15				
16	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	17
17				
18				
19	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	17
20				
21				
22				
23				
24	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	10
25				
26				
27				
28		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	13
29				
30	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	9
31				
32				
33				
34				
35	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	22
36				
37				
38	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	9
39				
40				
41				
42	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	NA
43				
44				
45	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	NA
46				
47				
48				
49				
50				
51		31b	Authorship eligibility guidelines and any intended use of professional writers	NA
52				
53				
54		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	NA
55				
56				
57				
58				
59				
60				

Appendices

Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	NA
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	13

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.

BMJ Open

Comparative Evaluation of Novel Screening Strategies for Colorectal Cancer Screening in China (TARGET-C): Study Protocol for a Multicenter Randomized Controlled Trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025935.R2
Article Type:	Protocol
Date Submitted by the Author:	04-Jan-2019
Complete List of Authors:	Chen, Hongda; Chinese Academy of Medical Sciences Cancer Institute and Hospital, Office of cancer screening Li, Ni; Chinese Academy of Medical Sciences Cancer Institute and Hospital, Office of cancer screening Shi, Jufang; National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Department of Cancer Epidemiology; Ren, Jian-song; National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Program Office for Cancer Screening Program in Urban China Liu, Chengcheng; Chinese Academy of Medical Sciences Cancer Institute and Hospital, Office of cancer screening Zhang, Yueming; Chinese Academy of Medical Sciences Cancer Institute and Hospital, Office of cancer screening Jiang, Zheng; Chinese Academy of Medical Sciences Cancer Institute and Hospital Zhang, Zhihui ; National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Department of Cancer Epidemiology Dai, Min; Program Office for Cancer Screening Program in Urban China, National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Primary Subject Heading:	Oncology
Secondary Subject Heading:	Epidemiology, Gastroenterology and hepatology, Health economics, Public health
Keywords:	Colorectal cancer, Early detection, Risk score, Advanced adenoma, Randomized controlled trial

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Comparative Evaluation of Novel Screening Strategies for Colorectal Cancer**
5 **Screening in China (TARGET-C): Study Protocol for a Multicenter Randomized**
6 **Controlled Trial**
7
8
9

10
11 Hongda Chen^{1*}, Ni Li^{1*}, Jufang Shi¹, Jiansong Ren¹, Chengcheng Liu¹, Yueming
12 Zhang², Zheng Jiang³, Zhihui Zhang⁴, Min Dai¹
13
14
15

16
17 ¹Office of Cancer Screening, National Cancer Center/National Clinical Research
18 Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking
19 Union Medical College, Beijing 100021, China
20
21

22
23 ²Department of Endoscopy, National Cancer Center/National Clinical Research Center
24 for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union
25 Medical College, Beijing 100021, China
26
27

28
29 ³ Department of Colorectal Surgery, National Cancer Center/National Clinical
30 Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences
31 and Peking Union Medical College, Beijing 100021, China
32
33

34
35 ⁴Department of Pathology, National Cancer Center/National Clinical Research Center
36 for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union
37 Medical College, Beijing 100021, China
38
39

40
41 *Hongda Chen and Ni Li contributed equally to this work.

42 **Address for Correspondence:** Prof. Min Dai, PhD, National Cancer Center/National
43 Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical
44 Sciences and Peking Union Medical College, Beijing 100021, China; Email:
45 daimin2002@hotmail.com; Tel: +86-10-8778-7394
46
47
48
49

50 **Word account:**3820
51
52
53
54
55
56
57
58
59
60

1 **Abstract**

2 **Introduction:** Screening for colorectal cancer (CRC) has been demonstrated to be
3 effective in reducing the burden of the disease. However, high-level evidence from
4 randomized controlled trials on the effectiveness of CRC screening modalities is still
5 lacking. We will conduct a large-scale multi-center randomized controlled trial for
6 CRC screening in China to evaluate the effectiveness and cost-effectiveness of
7 different CRC screening strategies.

8 **Methods and analysis:** 20,000 eligible participants aged 50-74 years are enrolled in five
9 provinces in China. After providing signed informed consent, the participants will be
10 randomized into one of the three screening groups: 1) one-time colonoscopy (N=4,000);
11 2) annual fecal immunochemical test (FIT) (N=8,000); 3) annual risk-adapted screening
12 strategy (N=8,000). For the risk adapted screening strategy, an established colorectal
13 cancer risk scoring system, the Asia-Pacific Colorectal Screening (APCS) score, will
14 be used. Participants at high-risk of CRC will be referred to colonoscopy and
15 participants at low-risk of CRC will be referred to take a FIT. Information on clinical
16 reports, epidemiological risk factors and health economic factors will be collected and
17 stored in a web-based data management system. We further request the participants to
18 donate blood, fecal and saliva samples before conducting colonoscopy. The primary
19 outcome is the detection rate of advanced colorectal neoplasia, and the secondary
20 outcomes include the CRC-related mortality rate, incidence rate of CRC, participation
21 rate and complication rate. The study will last for at least four years and the cohort will

1
2
3
4 1 be followed for ten years to adequately answer the scientific questions.
5
6
7

8 2 **Ethics and dissemination:** This study was approved by the Ethics Committee of the
9
10 3 National Cancer Center/Cancer Hospital, the Chinese Academy of Medical Sciences
11
12 4 and the Peking Union Medical College (18-013/1615). The results of the study will be
13
14 5 submitted for publication in peer-reviewed journals and will be discussed by policy and
15
16 6 decision makers.
17
18
19

20
21 7 **Trial registration:** Chinese Clinical Trial Registry (ChiCTR1800015506,
22
23 8 prospectively registered on 3 April 2018).
24
25

26 9 **Keywords:** Colorectal cancer, Early detection, Risk score, Advanced adenoma;
27
28
29 10 Randomized controlled trial
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- This is the first large-scale population-based colorectal cancer screening trial to compare the effectiveness and cost-effectiveness of three different screening strategies targeting adults aged 50 to 74 years old in China.
- A comprehensive health-economic evaluation will be performed to evaluate the cost-effectiveness of different screening arms and policy advice will therefore be provided based on the study findings.
- Prospective biospecimens collected before screening colonoscopy will be a valuable resource to explore novel biomarkers for early detection of colorectal cancer in further research.
- The sample sizes of the study population may not be adequate to compare the mortality reduction among the three screening arms after long-term follow-up.

1 **Introduction**

2 Colorectal Cancer (CRC) is the third most commonly diagnosed cancer and the second
3 most common cause of cancer-related death worldwide [1]. In China, with an estimate
4 of 376,300 newly diagnosed CRC cases and 191,000 CRC-related deaths in 2015, the
5 incidence ranked fourth and mortality ranked fifth of all cancer types. Notably, the
6 incidence and mortality of CRC has been steadily increasing over the past decades in
7 China [2]. Therefore, establishment of strategies on curbing the rising momentum of
8 CRC in China is strongly required.

9 Evidence from randomized controlled trials and observational studies have
10 demonstrated that screening could reduce the burden of CRC [3-5]. The established
11 screening modalities include colonoscopy, flexible sigmoidoscopy, and stool-based
12 tests (such as the fecal occult blood test (FOBT)), which have been widely used in many
13 screening programs worldwide [6-8]. Colonoscopy is the gold standard for CRC.
14 However, in population-based screening programs, colonoscopy is limited by low
15 compliance rate, potential complication, high cost and limited resources [9, 10].
16 Guaiac-based FOBT (gFOBT) was introduced in the 1980s. Although the sensitivity of
17 gFOBT for detecting CRC is not optimal, randomized controlled trials demonstrated
18 that screening by gFOBT yielded a reduction in CRC mortality [5]. To date, the newly
19 developed fecal immunochemical test (FIT) for hemoglobin showed superior
20 diagnostic performance than traditional gFOBT [11]. However, evidence from
21 randomized controlled trials to evaluate the screening efficacy of FIT is still lacking,

1 especially in the Chinese population [11].

2 Current guidelines recommend CRC screening for average-risk adults at a starting age
3 of 50 years old [12-15]. However, in countries with unbalanced and limited healthcare
4 resources, identification of high-risk populations and the development of risk-adapted
5 screening strategies would be potentially more cost-efficient than traditional screening
6 strategies. In previous studies, CRC risk scores based on environmental and/or generic
7 factors were developed, which typically presented moderate diagnostic efficacy [16].
8 Further combining risk scores with established screening modalities such as colonoscopy
9 and FIT was proposed and has shown promising diagnostic performance [13, 17, 18].
10 However, further validation of such risk-adapted screening strategies in large
11 prospective cohorts and randomized controlled trial are still sparse.

12 Searching for biomarkers in early detection of CRC is a promising research area.
13 Different types of biomarkers, including blood proteins, blood DNA methylation, fecal
14 DNA, fecal microbiota and oral microbiota, were reported to be associated with CRC
15 and could be potential targets for early detection of CRC [19]. Using the ongoing
16 screening trials to construct the biobank will be both time- and economic- saving, which
17 will also be an important platform for biomarker identification and validation for further
18 investigations.

19 In China, screening for CRC has been implemented in several regions over the past
20 decades [20, 21]. However, high-quality evidence of recommendation of CRC
21 screening in the Chinese population is still lacking and in high demand [20]. Therefore,

1 we planned to conduct a population-based, multicenter, randomized controlled trial
2 comparing colonoscopy, FIT and a novel risk-adapted screening strategy for CRC
3 screening in the Chinese population, with the following aims: 1) to establish a large-
4 scale CRC screening cohort with long-term follow-ups in China; 2) to evaluate the
5 effectiveness and cost-effectiveness of different CRC screening strategies in the
6 Chinese population; 3) to construct a large epidemiological and clinical database and a
7 biobank for further studies.

1 **Methods/Design**

2 ***Study setting and design***

3 This is a prospective, multicenter, randomized controlled trial comparing multiple
4 screening strategies on CRC screening in China. Participants who meet the study
5 inclusion and exclusion criteria are recruited in five provinces in China. We aim to
6 recruit at least 20,000 eligible participants at baseline. After obtaining signed informed
7 consent, eligible participants are randomly allocated into one of the following three
8 CRC screening groups in a 1:2:2 ratio (Figure 1). A four-year screening phase (with
9 one-year baseline screening and three years follow-up screening) will be conducted
10 for all participants, and a subsequent passive follow-up phase will also be implemented
11 until the scientific questions are answered adequately. Detailed information about
12 follow-up is shown in the following section.

13 1) ***Colonoscopy group (N=4,000)***: participants are recommended to undertake one-
14 time screening colonoscopy at baseline. Abnormal findings removed during
15 colonoscopy will be sent to pathology for further analysis. . For the following
16 years, all the participants will be interviewed to complete the follow-up
17 questionnaire annually.

18 2) ***FIT group (N=8,000)***: FITs are offered to the participants annually. Participants
19 who have positive FIT results are recommended to have a diagnostic
20 colonoscopy. Abnormal findings removed during colonoscopy will be sent to
21 pathology for further analysis.

1
2
3
4 1) 3) **Risk assessment group (N=8,000):** Colorectal cancer risk will be assessed using
5
6 an established CRC risk stratification scoring system at baseline. For participants
7
8 with high risk of CRC, screening colonoscopy will be offered. For participants
9
10 with low risk of CRC, FITs are offered and those with positive FIT results are
11
12 recommended to take further colonoscopy. During the annual follow-ups,
13
14 participants who have negative FIT results and participants who have not had a
15
16 screening colonoscopy will complete another round of risk assessment and the
17
18 same screening procedures as at baseline will be offered. For participants who
19
20 have already undertaken screening colonoscopy, no further screening intervention
21
22 will be provided but will complete a questionnaire annually during the study
23
24 period.
25
26
27
28
29
30
31
32

33 **Randomization and allocation procedure**

34
35
36 The randomization is conducted in a centralized controlled manner. The leading
37
38 institute (Cancer Hospital, Chinese Academy of Medical Sciences) is responsible for
39
40 the generation of the randomization scheme using a predefined seed by the statistical
41
42 software R. Before recruitment, the staff who are responsible for the recruitment at
43
44 each site and the participants are blinded to the allocation results. The allocation results
45
46 are revealed after successful registration of the subject in a web-based data system. At
47
48 the time of randomization, a unique Study Identification Number (SIN) is allocated to
49
50 the participant and will be used for the participants during the entire study period.
51
52
53
54
55
56
57

58 **Study population and recruitment**

59
60 Participants aged 50 to 74 years who live in the study region and are able to sign

1 informed consent are eligible for this study. Exclusion criteria are: 1) prior history of
2 colorectal cancer; 2) prior history of colonic resection; 3) undertaking any kind of
3 cancer related therapy (except for non-melanoma skin cancer); 4) prior colonic
4 examination, including colonoscopy, flexible sigmoidoscopy, CT colonography and
5 Barium enema within five years; 5) prior history of fecal occult blood test and fecal
6 DNA test within 1 year; 6) symptoms of lower gastrointestinal tract disease warranting
7 colonoscopic evaluation, including: a) more than one episode of rectal bleeding within
8 the past 6 months; b) documented iron deficiency anemia; c) significant documented
9 unintentional weight loss (>10% of baseline weight) over 6 months; 7) significant
10 comorbidity that would preclude benefit from screening or pose significant risk for the
11 performance of colonoscopy (e.g. severe lung disease, end-stage renal disease, end-
12 stage liver disease, severe heart failure, recent diagnosis of cancer (with the exception
13 of non-melanoma skin cancer).

14 Recruitment procedures will involve the following steps:

- 15 (1) Recruitment of potential participants aged 50 to 74 years in the selected
16 communities and check for eligibility by trained study staff;
- 17 (2) Signed written informed consent obtained from the eligible participants by
18 trained study staff;
- 19 (3) Registration of the participant in the web-based data management system, SIN
20 allocated, and randomization results revealed;
- 21 (4) Conducting respective intervention strategies per protocol;

1
2
3
4 **1 *Interventions***

5
6 **2 *Colonoscopy***

7
8
9 3 Standard clinical procedures of the screening colonoscopy will be followed, including
10
11 4 appointment, obtaining informed consent, routine blood test for infectious diseases
12
13 5 including hepatitis B virus (HBV), hepatitis C virus (HCV) and human
14
15 6 immunodeficiency virus (HIV) infections (if required by the hospitals, otherwise not
16
17 7 implemented), distribution of bowel preparation drugs, diet control, anesthesia (if
18
19 8 required by the participants) and colonoscopy examination. Colonoscopy will be
20
21 9 performed by experienced endoscopists who have more than five-year experience
22
23 10 performing colonoscopy. Abnormal findings during colonoscopy are carefully checked
24
25 11 under standard clinical procedures and tissue specimens are collected for further
26
27 12 pathology diagnosis. Any findings during colonoscopy are required to be photo
28
29 13 documented. Clinical information such as the examination duration, sedation status,
30
31 14 completeness, bowel preparation status, complication, polyp features (such as number,
32
33 15 position, size, color and shape), description of other abnormal findings, as well as
34
35 16 pathology diagnosis will be collected and documented in the web-based data
36
37 17 management system.
38
39
40
41
42
43
44
45
46
47
48

49 18 For quality control, an expert panel including experienced endoscopists and
50
51 19 pathologists will be formed. Each year, a selection of colonoscopy and pathology
52
53 20 documentation will be assessed by the expert panel, and review reports will be
54
55 21 transferred to the respective physicians about their performance.
56
57
58
59
60

1
2
3
4 1 *Fecal immunochemical test (FIT)*
5

6 2 Fecal immunochemical tests for human hemoglobin are provided by the study staff to
7
8 3 participants after successful registration in this study. The FIT used in this study is a
9
10 4 self-administered qualitative test, providing an endpoint that is read as positive or
11
12 5 negative by eye if the fecal hemoglobin concentration exceeds the manufacturer-
13
14 6 specific threshold (100 ng Hb/mL buffer, corresponds to 10 µg Hb/g feces). A previous
15
16 7 pilot analysis demonstrated that the sensitivities for detecting CRC and advanced
17
18 8 adenomas were 76% and 37%, respectively, at a specificity of 92% (data not publicly
19
20 9 available). The participants can submit the results to the study website along with the
21
22 10 picture of the test window or will be interviewed by the study staff for the test results
23
24 11 within three days of distributing the FIT. For participants having invalid test results,
25
26 12 new test devices will be provided until a valid test result is available. Participants are
27
28 13 contacted and a follow up colonoscopy will be arranged if they are confirmed to have
29
30 14 positive FIT results.
31
32
33
34
35
36
37
38
39
40

41 15 *Colorectal cancer risk assessment*
42

43
44 16 In this study, an established colorectal cancer risk scoring system, the Asia-Pacific
45
46 17 Colorectal Screening (APCS) score [22, 23], will be used. The APCS score is derived
47
48 18 based on five common risk factors of CRC, including age, sex, family history of CRC
49
50 19 in a first-degree relative, smoking and BMI (Body Mass Index). In a previous study
51
52 20 conducted in Hong Kong, the sensitivity, specificity, positive predictive value and
53
54 21 negative predictive value of the risk score for detecting advanced neoplasms were
55
56 22 33.3%, 81.0%, 5.17% and 97.5%, respectively, defining score ≥ 4 as high risk for CRC
57
58
59
60

1 [23]. Based on previous evidences, we designed the risk score system and detailed
2 information is shown in Table 1. Generally, for the risk-adapted screening group,
3 participants are asked to fill in a questionnaire including the above mentioned risk
4 factors. Participants with a score ≥ 4 are defined to be at high-risk of CRC, and
5 participants with a score < 4 are defined to have a low-risk of CRC. Participants will be
6 informed about their evaluation results and receive the respective screening
7 intervention as per the study protocol.

8 ***Patient and Public Involvement***

9 During the process of recruitment, the participants will be informed about the research
10 question, study design and screening intervention by study staff. The participants can
11 quit the study and withdrawn the informed consent at any time based on their priorities,
12 experiences or preferences. The participant and public had no role in the study design,
13 recruitment and conduct of the study. All the screening intervention will be provided to
14 the participants at no cost (compensated by this study), except for the subsequent
15 therapeutic costs which must be paid by the participants themselves. The burden of the
16 intervention and potential subsequent therapeutic procedure will be informed by the
17 study staff at the recruitment phase. A report summarizing the screening results will be
18 disseminated to the participants by study staff.

20 ***Biospecimen collection and handling***

21 Participants who need to undertake colonoscopy are invited to donate stool, saliva and
22 blood samples prior to colonoscopy. Standard Operating Procedures (SOPs) regarding

1 biospecimen collection, handling and storage have been formulated and will be
2 followed.

3 For stool samples, collection devices (including sample collection vials, ice bags,
4 isothermal bags and operation brochures) are distributed. At the day before
5 colonoscopy, participants are suggested to collect raw stool samples before taking
6 bowel cleaning drugs for colonoscopy. The participants are recommended to store the
7 samples in the freezer or in the isothermal bags with ice bags until transported to the
8 hospital. The samples are stored in the freezer (-80°C) immediately for future use when
9 received.

10 For saliva samples, participants are provided with sample collection tubes (with oral
11 DNA stabilization buffer) during their visit to the hospital before colonoscopy. Study
12 staff will guide the participants for the saliva sample collection procedure. Collected
13 samples will be aliquoted immediately and stored in the freezer (-80°C) for future use.

14 For blood samples, around 10ml vein blood samples (including 5ml EDTA
15 anticoagulated blood and 5ml non-anticoagulation blood) will be drawn from the
16 participants during their visit to the hospital before colonoscopy. Under the SOPs, blood
17 samples are centrifuged, aliquoted and then stored in the freezer (-80°C) for future use.

18 ***Follow up***

19 Both active follow-up and passive follow-up will be conducted in this study. For the
20 active follow-up, all the participants will be interviewed by trained study staff by

1 telephone call, home visit or other contact methods for collection of information such
2 as physical examination, health status and outcome. For the passive follow-up, linkage
3 data from cancer registry system, death surveillance system, medical insurance and
4 claim database will be used to track the outcome of the participants.

5 ***Contamination evaluation***

6 During the study period, the study team will contact the participants to evaluate the
7 status of CRC beyond the study protocol. The extra screening examinations conducted
8 by the participant during the study period are not allocated by the randomization, and
9 therefore may introduce contamination to the study results. To evaluate the
10 contamination status of this study, all participants who are screened to have negative
11 findings will complete one round of questionnaire interview in the fourth year of the
12 study. Information regarding the history of diagnostic or screening colonic examination
13 will be collected and assessed. We anticipate controlling the contamination rate to be
14 below 10%. For the final analysis report, the contamination will be taken into
15 consideration to estimate the screening effects.

16 ***Outcome measures***

17 The primary outcome is the detection rate of advanced colorectal neoplasia (CRC and
18 advanced adenoma). The secondary outcomes include mortality rate of CRC, detection
19 rate of any neoplasm, compliance rate and complication rate.

20 ***Data collection***

21 *Epidemiological risk factor investigation*

1
2
3
4 1 A standardized epidemiological questionnaire will be administered by trained
5
6 2 interviewers to all participants to investigate the risk factors of colorectal cancer.
7
8
9 3 Information including sociodemographic factors, history of bowel disease and clinical
10
11 4 treatment, living habits, disease history and family history of cancer are collected and
12
13
14 5 stored in the web-based data management system.

6 *Health economic information*

7 Comprehensive health economic evaluation will be conducted. Questionnaires
8 including the EuroQol five dimensions questionnaire (EQ-5D) and EQ-5D-5L will be
9 used to measure the health state of the participants. The direct costs on materials,
10 equipment, personnel, drug and other resources will be collected from all participating
11 sites to estimate the cost-effectiveness of different screening strategies in this clinical
12 trial.

13 **Data monitoring committee**

14 A data monitoring committee composed of epidemiologists, endoscopists, pathologists
15 and colorectal surgeons will monitor the data collection process and analyses. All data
16 will be transmitted to the Central Data Management Team in the National Cancer
17 Center of China/Cancer Hospital Chinese Academy of Medical Sciences, where the
18 databases are constructed, and analyses are performed. In addition, any adverse events
19 (e.g., perforation, bleeding) will be recorded in standardized forms by the study sites
20 and will also be reported to the Ethics Committee for record.

21 **Statistical Considerations**

22 *Sample size*

1 Sample sizes were calculated based on the evaluation of primary outcomes, i.e.,
2 advanced colorectal neoplasia detection rate. The hypothesis was that the advanced
3 neoplasia detection rate of the risk-adapted screening group was superior to the FIT
4 group and non-inferior to the colonoscopy group. According to previous studies, the
5 reference advanced neoplasia detection rate of colonoscopy, FIT and risk-adapted
6 screening groups were 6.5%, 1.8% and 5.0%, respectively [13, 24]. We assumed the
7 compliance rate was 50% to 70% for colonoscopy, 60%-90% for FIT and 60%-90% for
8 the risk-adapted screening strategy and an overall loss-to-follow-up of 10%. For the
9 comparison between the risk-adapted screening strategy group and the FIT group at
10 different scenarios of the compliance rates, the largest sample size needed was 6550
11 when we set the significance level of $\alpha=0.05$, the power of 0.8 and superiority margin
12 (δ) of -0.005. For the comparison between the risk-adapted screening group and the
13 colonoscopy group, when assuming the respective compliance rates were 85% and 60%,
14 the required sample sizes were 6032 and 3016, respectively, when we set the
15 significance level of $\alpha=0.05$, the power of 0.8, non-inferiority margin (δ) of -0.001.
16 Therefore, the sample sizes of this study design (4000 for the colonoscopy group, 8000
17 for the FIT group and 8000 for the risk-adapted screening group) will accomplish the
18 study hypotheses.

19 **Statistical analyses**

20 The primary outcome analysis will be a comparison of histologically confirmed CRC
21 and advanced adenoma between the three intervention arms taking into consideration
22 the compliance rate. Intention-to-treat and per-protocol analyses will be conducted. For

1 secondary outcomes, mortality rate will be calculated as the ratio of the number of
2 deaths due to CRC to the person-years at risk for each group. Person-years will be
3 estimated from the time of randomization to the diagnosis date of CRC, death or
4 censoring at the end of the study. The incidence rate will be estimated in a similar way.
5 Chi-square tests and t-tests are used to compare categorical and continuous variables
6 between the two groups, respectively. The Cox proportional hazards regression model
7 is adopted to examine the difference of incidence and mortality between different
8 screening groups. For health economic evaluation, Markov models will be developed
9 to evaluate the cost-effectiveness of different screening strategies for CRC in China.
10 Statistical software, such as SAS software (version 9.2; SAS Institute, Cary, NC, USA),
11 R (version 3.4.1, R Foundation for Statistical Computing, Vienna, Austria) and
12 TreeAge Pro 2016 (TreeAge Software, Inc., MA, USA), will be used in the data
13 analyses.

15 ***Ethics and dissemination***

16 This study was approved by Ethics Committee of the National Cancer Center/Cancer
17 Hospital, the Chinese Academy of Medical Sciences and the Peking Union Medical
18 College (approved number:18-013/1615) and the protocol was registered in the Chinese
19 Clinical Trial Registry (registration number: ChiCTR1800015506).

20 The results of the study will be submitted for publication to peer-reviewed journals and
21 conferences following the Consolidated Standards of Reporting Trials guidelines. The
22 results will be discussed by policy and decision makers. Access to the detailed research

1
2
3
4 1 plan, participant-level dataset and statistical analysis code will be granted based on
5
6 2 reasonable requests after the publication of the study.
7
8

9
10 3 ***Trial status***

11
12 4 This screening trial is currently in the participant enrolment phase. 1600 eligible
13
14 5 participants have been randomized and are under respective colorectal cancer screening
15
16 6 as of August 2018. We anticipate the full analysis to be finalized in December 2021.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Discussion**

2 Our study aims to evaluate the effectiveness and cost-effectiveness of three strategies
3 for CRC screening in China. To our knowledge, this is the first large-scale randomized
4 controlled trial on CRC screening based on a community population in China.
5 Colonoscopy is the gold standard for CRC screening, and FIT is the most widely used
6 non-invasive CRC screening test. However, the magnitude of the effect of colonoscopy
7 and FIT in population-based CRC screening is uncertain due to lack of evidence from
8 randomized controlled trials. To date, there are three large-scale randomized controlled
9 trials (SCREESCO, CONFIRM and COLONPREV) comparing colonoscopy or FIT
10 screening with regard to CRC incidence and mortality [25-28]. All the three trials are
11 currently ongoing and conducted in Europe and North America. Our study will be the
12 first large-scale CRC screening trial in Asia. In addition, we also include a novel risk-
13 adapted screening strategy in our trial, which incorporates risk assessment with
14 established screening methods. Our study will provide strong evidence on the
15 effectiveness and feasibility of different strategies for CRC screening in China.

16 In recent years, the burden of CRC has been increasing in East-Asia which has been
17 explained by changes in diet and a westernized lifestyle [29]. Countries including China,
18 Japan and South Korea have implemented organized screening programs. For instance,
19 in Japan, the CRC screening program initiated in 1992, uses FIT as the main screening
20 method and the cost is covered by the national health insurance [30]. In China,
21 individuals aged 40-74 years are screened with FOBT or colonoscopy based on clinical

1 risk indexes in some regions but not the entire country [20]. Furthermore, the most
2 appropriate techniques for different populations in China are still under debate. The
3 results of our study will therefore provide high-level evidence to design CRC screening
4 strategy for China and provides essential references for other countries.

5 In this study, we plan to finish the baseline recruitment and baseline screening before
6 June of 2019 and will continue to have a total of three rounds of the screening
7 intervention FIT group and the risk-adapted screening group. Long term passive follow-
8 up will also be conducted to obtain the health outcomes of the participants and will be
9 used for evaluation of the long-term effect of CRC screening. There are several
10 strengths of our study. Firstly, we use a prospective randomized design which would
11 minimize the selection bias and provide high-level evidence compared to other study
12 designs such as cross-sectional studies. In addition, except for active follow-ups, we
13 will also implement passive follow-ups using multiple resources such as cancer registry,
14 death surveillance system, medical insurance and claim databases to track the outcomes
15 of all the study participants. We will also construct a large biobank using prospectively
16 collected specimens. Such a biobank will serve as an essential platform for biomarker
17 identification and validation for further investigations.

18 The major challenges of this study are the control of loss to follow-up and the quality
19 control of a multi-center project. To address such concern, we will employ experienced
20 study staff to contact and visit the participants regularly. Moreover, a health education
21 campaign will be conducted to improve the health literacy by means of lectures, videos,

1 advertisement and social media. For the quality control, we will build an expert panel
2 including experts of epidemiologists, endoscopists, pathologists and surgeons. A
3 capacity training workshop will be held annually, and a selection of study reports will
4 be reviewed to ensure the study quality.

5 To sum up, this is a large-scale multi-center randomized controlled trial, comparing
6 three strategies for CRC screening. Successful implementation of this study will
7 provide strong evidence on the effectiveness and cost-effectiveness of CRC screening
8 and provide essential references for policy-makers to design national screening
9 programs in the future.

1 **Authors' contributions**

2 HC, NL and MD designed the study protocol, HC and NL drafted the manuscript, JS,
3 JR, CL, YZ, ZJ, ZZ and MD critically reviewed and revised the manuscript. All authors
4 read and approved the final manuscript.

5 **Funding statement:**

6 This study was sponsored by CAMS Innovation Fund for Medical Sciences (2017-I2M-
7 1-006) and National Natural Science Foundation of China (81703309). The funder had
8 no role in the design and conduct of the study; collection, management, analysis, and
9 interpretation of the data; preparation, review, or approval of the manuscript; and
10 decision to submit the manuscript for publication.

11 **Competing interests**

12 The authors declare that they have no competing interests.

13 **Acknowledgements**

14 The authors would like to thank all participating sites: Zhejiang Cancer Hospital, Anhui
15 Provincial Cancer Hospital, Xuzhou Cancer Hospital, Hunan Cancer Hospital Yunnan
16 Cancer Hospital, Center for Disease Control and Prevention of the participating cities,
17 the community staff and participants for their contribution. We also thank Dr. Prudence
18 Carr for the English proof reading of this manuscript.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, and Jemal A, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*, 2018. 68(6): 394-424.
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, and He J, Cancer statistics in China, 2015. *CA Cancer J Clin*, 2016. 66(2): 115-32.
3. Zorzi M, Fedeli U, Schievano E, Bovo E, Guzzinati S, Baracco S, Fedato C, Saugo M, and Dei Tos AP, Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test. *Gut*, 2015. 64(5): 784-90.
4. Brenner H, Stock C, and Hoffmeister M, Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. *Bmj*, 2014. 348: g2467.
5. Hewitson P, Glasziou P, Watson E, Towler B, and Irwig L, Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. *Am J Gastroenterol*, 2008. 103(6): 1541-9.
6. Brenner H, Kloor M, and Pox CP, Colorectal cancer. *Lancet*, 2014. 383(9927): 1490-502.
7. Schreuders EH, Ruco A, Rabeneck L, Schoen RE, Sung JJ, Young GP, and Kuipers EJ, Colorectal cancer screening: a global overview of existing programmes. *Gut*, 2015. 64(10): 1637-49.
8. Whitlock EP, Lin JS, Liles E, Beil TL, and Fu R, Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. *Ann Intern Med*, 2008. 149(9): 638-58.
9. Senore C, Inadomi J, Segnan N, Bellisario C, and Hassan C, Optimising colorectal cancer screening acceptance: a review. *Gut*, 2015. 64(7): 1158-77.
10. Robertson DJ, Kaminski MF, and Bretthauer M, Effectiveness, training and quality assurance of colonoscopy screening for colorectal cancer. *Gut*, 2015. 64(6): 982-90.
11. Tinmouth J, Lansdorp-Vogelaar I, and Allison JE, Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know. *Gut*, 2015. 64(8): 1327-37.
12. Lin JS, Piper MA, Perdue LA, Rutter CM, Webber EM, O'Connor E, Smith N, and Whitlock EP, Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *Jama*, 2016. 315(23): 2576-94.
13. Chiu HM, Ching JY, Wu KC, Rerknimitr R, Li J, Wu DC, Goh KL, Matsuda T, Kim HS, Leong R, Yeoh KG, Chong VH, Sollano JD, Ahmed F, Menon J, and Sung JJ, A Risk-Scoring System Combined With a Fecal Immunochemical Test Is Effective in Screening High-Risk Subjects for Early Colonoscopy to Detect Advanced Colorectal Neoplasms. *Gastroenterology*, 2016. 150(3): 617-25.e3.
14. Provenzale D, Jasperson K, Ahnen DJ, Aslanian H, Bray T, Cannon JA, David DS, Erwin D, Ford JM, Giardiello FM, Gupta S, Halverson AL, Hamilton SR, Hampel H, Ismail MK, Klapman JB, Larson DW, Lazenby AJ, Lynch PM, Mayer RJ, Ness RM, Rao MS, Regenbogen SE, Shike M, Steinbach G, Weinberg D, Dwyer MA, Freedman-Cass DA, and Darlow S, Colorectal Cancer Screening, Version 1.2015. *J Natl Compr Canc Netw*, 2015. 13(8): 959-68; quiz 68.
15. Armaroli P, Villain P, Suonio E, Almonte M, Anttila A, Atkin WS, Dean PB, de Koning HJ, Dillner L, Herrero R, Kuipers EJ, Lansdorp-Vogelaar I, Minozzi S, Paci E, Regula J, Tornberg S, and

- 1
2
3 Segnan N, European Code against Cancer, 4th Edition: Cancer screening. *Cancer Epidemiol*,
4 2015. 39 Suppl 1: S139-52.
- 5
6 16. Win AK, Macinnis RJ, Hopper JL, and Jenkins MA, Risk prediction models for colorectal cancer:
7 a review. *Cancer Epidemiol Biomarkers Prev*, 2012. 21(3): 398-410.
- 8
9 17. Jung YS, Park CH, Kim NH, Park JH, Park DI, and Sohn CI, A combination of clinical risk
10 stratification and fecal immunochemical test is useful for identifying persons with high priority
11 of early colonoscopy. *Dig Liver Dis*, 2018. 50(3): 254-59.
- 12
13 18. Cubiella J, Digby J, Rodriguez-Alonso L, Vega P, Salve M, Diaz-Ondina M, Strachan JA, Mowat
14 C, McDonald PJ, Carey FA, Godber IM, Younes HB, Rodriguez-Moranta F, Quintero E, Alvarez-
15 Sanchez V, Fernandez-Banares F, Boadas J, Campo R, Bujanda L, Garayoa A, Ferrandez A, Pinol
16 V, Rodriguez-Alcalde D, Guardiola J, Steele RJ, and Fraser CG, The fecal hemoglobin
17 concentration, age and sex test score: Development and external validation of a simple
18 prediction tool for colorectal cancer detection in symptomatic patients. *Int J Cancer*, 2017.
19 140(10): 2201-11.
- 20
21 19. Dickinson BT, Kisiel J, Ahlquist DA, and Grady WM, Molecular markers for colorectal cancer
22 screening. *Gut*, 2015. 64(9): 1485-94.
- 23
24 20. Goss PE, Strasser-Weippl K, Lee-Bychkovsky BL, Fan L, Li J, Chavarri-Guerra Y, Liedke PE,
25 Pramesh CS, Badovinac-Crnjevic T, Sheikine Y, Chen Z, Qiao YL, Shao Z, Wu YL, Fan D, Chow
26 LW, Wang J, Zhang Q, Yu S, Shen G, He J, Purushotham A, Sullivan R, Badwe R, Banavali SD,
27 Nair R, Kumar L, Parikh P, Subramanian S, Chaturvedi P, Iyer S, Shastri SS, Digumarti R, Soto-
28 Perez-de-Celis E, Adilbay D, Semiglazov V, Orlov S, Kaidarova D, Tsimafeyeu I, Tatishchev S,
29 Danishevskiy KD, Hurlbert M, Vail C, St Louis J, and Chan A, Challenges to effective cancer
30 control in China, India, and Russia. *Lancet Oncol*, 2014. 15(5): 489-538.
- 31
32 21. Guo C, Liu Q, and Dai M, [Colorectal cancer screening: situation and prospect]. *Zhonghua Yu*
33 *Fang Yi Xue Za Zhi*, 2015. 49(5): 377-80.
- 34
35 22. Sung JY, Wong MCS, Lam TYT, Tsoi KKF, Chan VCW, Cheung W, and Ching JYL, A modified
36 colorectal screening score for prediction of advanced neoplasia: A prospective study of 5744
37 subjects. *J Gastroenterol Hepatol*, 2018. 33(1): 187-94.
- 38
39 23. Yeoh KG, Ho KY, Chiu HM, Zhu F, Ching JY, Wu DC, Matsuda T, Byeon JS, Lee SK, Goh KL, Sollano
40 J, Rerknimitr R, Leong R, Tsoi K, Lin JT, and Sung JJ, The Asia-Pacific Colorectal Screening score:
41 a validated tool that stratifies risk for colorectal advanced neoplasia in asymptomatic Asian
42 subjects. *Gut*, 2011. 60(9): 1236-41.
- 43
44 24. Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, Ahlquist DA, and Berger
45 BM, Multitarget stool DNA testing for colorectal-cancer screening. *N Engl J Med*, 2014. 370(14):
46 1287-97.
- 47
48 25. Kaminski MF, Bretthauer M, Zauber AG, Kuipers EJ, Adami HO, van Ballegooijen M, Regula J,
49 van Leerdam M, Stefansson T, Pahlman L, Dekker E, Hernan MA, Garborg K, and Hoff G, The
50 NordICC Study: rationale and design of a randomized trial on colonoscopy screening for
51 colorectal cancer. *Endoscopy*, 2012. 44(7): 695-702.
- 52
53 26. Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanasa A, Andreu M, Carballo F, Morillas
54 JD, Hernandez C, Jover R, Montalvo I, Arenas J, Laredo E, Hernandez V, Iglesias F, Cid E,
55 Zubizarreta R, Sala T, Ponce M, Andres M, Teruel G, Peris A, Roncales MP, Polo-Tomas M, Bessa
56 X, Ferrer-Armengou O, Grau J, Serradesanferm A, Ono A, Cruzado J, Perez-Riquelme F, Alonso-
57 Abreu I, de la Vega-Prieto M, Reyes-Melian JM, Cacho G, Diaz-Tasende J, Herreros-de-Tejada
58
59
60

- 1
2
3 A, Poves C, Santander C, and Gonzalez-Navarro A, Colonoscopy versus fecal immunochemical
4 testing in colorectal-cancer screening. N Engl J Med, 2012. 366(8): 697-706.
5
6 27. CONFRIM trial at <http://www.clinicaltrials.gov/ct2/show/NCT01239082> (accessed 28 April
7 2018).
8
9 28. Screesco trial at <http://www.clinicaltrials.gov/ct2/show/NCT02078804> (accessed 28 April
10 2018).
11
12 29. Sung JJ, Lau JY, Goh KL, and Leung WK, Increasing incidence of colorectal cancer in Asia:
13 implications for screening. Lancet Oncol, 2005. 6(11): 871-6.
14
15 30. Saito H, Colorectal cancer screening using immunochemical faecal occult blood testing in Japan.
16 J Med Screen, 2006. 13 Suppl 1: S6-7.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Risk factors and respective advocated points of the Asia-Pacific Colorectal Screening (APCS) score used in this trial

Risk factor	Criteria	Points
Age (years)	<50	0
	50-69	1
	≥70	2
Sex	Female	0
	Male	1
Family history of colorectal cancer in a first-degree relative	Absent	0
	Present	1
Smoking	No	0
	Current or past	1
BMI	<23	0
	≥23	1

Abbreviations: BMI, Body Mass Index, calculated as Weight (kg)/height²(meter²)

1
2
3
4
5 **Figure Legend**
6
7

8
9 Figure 1. SPIRIT flow diagram of the study design
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Figure 1. SPIRIT flow diagram of the study design

338x190mm (133 x 120 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Page
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	4
	2b	All items from the World Health Organization Trial Registration Data Set	4
Protocol version	3	Date and version identifier	NA
Funding	4	Sources and types of financial, material, and other support	22
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	22
	5b	Name and contact information for the trial sponsor	NA
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	22
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	11
Introduction			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	5
	6b	Explanation for choice of comparators	5 and 6
Objectives	7	Specific objectives or hypotheses	5 and 6
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	7

Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	8
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	10
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	8 and 9
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	10
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	10
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	11
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	14
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	8
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	15
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	10

Methods: Assignment of interventions (for controlled trials)

Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	9
---------------------	-----	--	---

1				
2	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central	9
3	concealment		telephone; sequentially numbered, opaque, sealed envelopes),	
4	mechanism		describing any steps to conceal the sequence until interventions are	
5			assigned	
6				
7	Implementation	16c	Who will generate the allocation sequence, who will enrol participants,	9
8			and who will assign participants to interventions	
9				
10	Blinding	17a	Who will be blinded after assignment to interventions (eg, trial	9
11	(masking)		participants, care providers, outcome assessors, data analysts), and	
12			how	
13				
14		17b	If blinded, circumstances under which unblinding is permissible, and	9
15			procedure for revealing a participant's allocated intervention during	
16			the trial	
17				

Methods: Data collection, management, and analysis

18				
19				
20	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other	15
21	methods		trial data, including any related processes to promote data quality (eg,	
22			duplicate measurements, training of assessors) and a description of	
23			study instruments (eg, questionnaires, laboratory tests) along with	
24			their reliability and validity, if known. Reference to where data	
25			collection forms can be found, if not in the protocol	
26				
27				
28		18b	Plans to promote participant retention and complete follow-up,	13
29			including list of any outcome data to be collected for participants who	
30			discontinue or deviate from intervention protocols	
31				
32	Data	19	Plans for data entry, coding, security, and storage, including any	15
33	management		related processes to promote data quality (eg, double data entry;	
34			range checks for data values). Reference to where details of data	
35			management procedures can be found, if not in the protocol	
36				
37	Statistical	20a	Statistical methods for analysing primary and secondary outcomes.	16
38	methods		Reference to where other details of the statistical analysis plan can be	
39			found, if not in the protocol	
40				
41				
42		20b	Methods for any additional analyses (eg, subgroup and adjusted	16
43			analyses)	
44				
45		20c	Definition of analysis population relating to protocol non-adherence	16
46			(eg, as randomised analysis), and any statistical methods to handle	
47			missing data (eg, multiple imputation)	
48				

Methods: Monitoring

49				
50				
51	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role	11
52			and reporting structure; statement of whether it is independent from	
53			the sponsor and competing interests; and reference to where further	
54			details about its charter can be found, if not in the protocol.	
55			Alternatively, an explanation of why a DMC is not needed	
56				
57				
58				
59				
60				

	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	NA
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	15
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	NA
Ethics and dissemination			
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	17
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	17
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	10
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	13
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	9
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	22
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	9
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	NA
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	NA
	31b	Authorship eligibility guidelines and any intended use of professional writers	NA
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	NA

Appendices

Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	NA
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	13

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.

BMJ Open

Comparative Evaluation of Novel Screening Strategies for Colorectal Cancer Screening in China (TARGET-C): A Study Protocol for a Multicenter Randomized Controlled Trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025935.R3
Article Type:	Protocol
Date Submitted by the Author:	25-Feb-2019
Complete List of Authors:	Chen, Hongda; Chinese Academy of Medical Sciences Cancer Institute and Hospital, Office of cancer screening Li, Ni; Chinese Academy of Medical Sciences Cancer Institute and Hospital, Office of cancer screening Shi, Jufang; National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Department of Cancer Epidemiology; Ren, Jian-song; National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Program Office for Cancer Screening Program in Urban China Liu, Chengcheng; Chinese Academy of Medical Sciences Cancer Institute and Hospital, Office of cancer screening Zhang, Yueming; Chinese Academy of Medical Sciences Cancer Institute and Hospital, Office of cancer screening Jiang, Zheng; Chinese Academy of Medical Sciences Cancer Institute and Hospital Zhang, Zhihui ; National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Department of Cancer Epidemiology Dai, Min; Program Office for Cancer Screening Program in Urban China, National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Primary Subject Heading:	Oncology
Secondary Subject Heading:	Epidemiology, Gastroenterology and hepatology, Public health
Keywords:	Colorectal cancer, Early detection, Risk score, Advanced adenoma, Randomized controlled trial

SCHOLARONE™
Manuscripts

1
2
3
4 **Comparative Evaluation of Novel Screening Strategies for Colorectal Cancer**
5 **Screening in China (TARGET-C): A Study Protocol for a Multicenter Randomized**
6 **Controlled Trial**
7
8
9

10
11 Hongda Chen^{1*}, Ni Li^{1*}, Jufang Shi¹, Jiansong Ren¹, Chengcheng Liu¹, Yueming
12 Zhang², Zheng Jiang³, Zhihui Zhang⁴, Min Dai¹
13
14
15

16
17 ¹Office of Cancer Screening, National Cancer Center/National Clinical Research
18 Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking
19 Union Medical College, Beijing 100021, China
20
21

22
23 ²Department of Endoscopy, National Cancer Center/National Clinical Research Center
24 for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union
25 Medical College, Beijing 100021, China
26
27

28
29 ³Department of Colorectal Surgery, National Cancer Center/National Clinical
30 Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences
31 and Peking Union Medical College, Beijing 100021, China
32
33

34
35 ⁴Department of Pathology, National Cancer Center/National Clinical Research Center
36 for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union
37 Medical College, Beijing 100021, China
38
39

40
41 *Hongda Chen and Ni Li contributed equally to this work.

42 **Address for Correspondence:** Prof. Min Dai, PhD, National Cancer Center/National
43 Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical
44 Sciences and Peking Union Medical College, Beijing 100021, China; Email:
45 daimin2002@hotmail.com; Tel: +86-10-8778-7394
46
47
48
49

50
51 **Word count:** 3632
52
53
54
55
56
57
58
59
60

1 **Abstract**

2 **Introduction:** Screening for colorectal cancer (CRC) is effective in reducing the
3 disease burden. However, high-level evidence from randomized controlled trials on
4 the effectiveness of CRC screening modalities is still lacking. We will conduct a large-
5 scale multi-center randomized controlled trial in China to evaluate the effectiveness
6 and cost-effectiveness of different CRC screening strategies.

7 **Methods and analysis:** 20,000 eligible participants aged 50-74 years are enrolled in five
8 provinces in China. After providing signed informed consent, the participants will be
9 randomized into one of the three screening groups: 1) one-time colonoscopy (N=4,000);
10 2) annual fecal immunochemical test (FIT) (N=8,000); and 3) annual risk-adapted
11 screening strategy (N=8,000). The risk-adapted screening strategy will use an
12 established CRC risk scoring system, the Asia-Pacific Colorectal Screening (APCS)
13 score. Participants at high-risk of CRC will be referred for colonoscopy, while
14 participants at low risk will be referred for an FIT. Information on clinical reports,
15 epidemiological risk factors, and health economic factors will be collected and stored
16 in a web-based data management system. We will further request the participants to
17 donate blood, fecal, and saliva samples before conducting the colonoscopy. The
18 primary outcome will be the detection rate of advanced colorectal neoplasia and the
19 secondary outcomes will include the rates of CRC-related mortality, incidence of CRC,
20 participation, and complications. The study will last for at least 4 years and the cohort
21 will be followed for 10 years to adequately answer the scientific questions.

1
2
3
4 1 **Ethics and dissemination:** This study was approved by the Ethics Committee of the
5
6 2 National Cancer Center/Cancer Hospital, the Chinese Academy of Medical Sciences,
7
8
9 3 and Peking Union Medical College (18-013/1615). The results of the study will be
10
11 4 submitted for publication in peer-reviewed journals and will be discussed by policy and
12
13
14 5 decision makers.

16
17 6 **Trial registration:** Chinese Clinical Trial Registry (ChiCTR1800015506,
18
19 7 prospectively registered on 3 April 2018).
20
21
22

23 8
24
25 9 **Keywords:** Colorectal cancer, Early detection, Risk score, Advanced adenoma,
26
27 10 Randomized controlled trial
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- This is the first large-scale population-based trial in China to compare the effectiveness and cost-effectiveness of three different colorectal cancer screening strategies targeting adults aged 50–74 years.
- A comprehensive health-economic evaluation will be performed to evaluate the cost-effectiveness of the different screening arms and policy advice will, therefore, be provided based on the study findings.
- Prospective biospecimens collected before screening colonoscopy will be a valuable resource to explore novel biomarkers for the early detection of colorectal cancer in further research.
- The sample sizes of the study population may not be adequate to compare mortality reduction among the three screening arms after long-term follow-up.

1 INTRODUCTION

2 Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second
3 most common cause of cancer-related death worldwide.[1] In China, with estimated
4 376,300 newly diagnosed CRC cases and 191,000 CRC-related deaths in 2015, the
5 incidence and mortality ranked fourth and fifth of all cancer types, respectively. The
6 incidence and mortality of CRC in China have been steadily increasing in recent
7 decades.[2] Therefore, the establishment of strategies to curb the rising momentum of
8 CRC in China is strongly required.

9 Evidence from randomized controlled trials and observational studies has demonstrated
10 that screening could reduce the burden of CRC.[3-5] The established screening
11 modalities include colonoscopy, flexible sigmoidoscopy, and stool-based tests such as
12 the fecal occult blood test (FOBT), which have been widely used in many screening
13 programs worldwide.[6-8] Colonoscopy is the gold standard for CRC. However, in
14 population-based screening programs, colonoscopy is limited by low compliance rates,
15 potential complications, high costs, and limited resources.[9, 10] Guaiac-based FOBT
16 (gFOBT) was introduced in the 1980s. Although the sensitivity of gFOBT for detecting
17 CRC is not optimal, randomized controlled trials demonstrated that screening by
18 gFOBT yielded a reduction in CRC mortality.[5] The newly developed fecal
19 immunochemical test (FIT) for hemoglobin showed superior diagnostic performance
20 compared to that of traditional gFOBT.[11] However, evidence from randomized
21 controlled trials evaluating the screening efficacy of FIT is still lacking, especially in

1 the Chinese population.[11]

2 Current guidelines recommend CRC screening for average-risk adults starting at 50
3 years of age.[12-15] However, in countries with unbalanced and limited healthcare
4 resources, identification of high-risk populations and the development of risk-adapted
5 screening strategies may be more cost-efficient than traditional screening strategies.

6 Previous studies developed CRC risk scores based on environmental and/or genetic
7 factors, which typically presented moderate diagnostic efficacy.[16] The combination
8 of risk scores and established screening modalities such as colonoscopy and FIT had
9 been proposed and has shown promising diagnostic performance.[13, 17, 18] However,
10 further validation of such risk-adapted screening strategies in large prospective cohorts
11 and randomized controlled trial are sparse.

12 Identification of biomarkers for the early detection of CRC is a promising area of
13 research. Different types of biomarkers, including blood proteins, blood DNA
14 methylation, fecal DNA, fecal microbiota, and oral microbiota, have been associated
15 with CRC and could be targets for the early detection of CRC.[19] The use of ongoing
16 screening trials to construct a biobank will be both time-saving and economical and will
17 also be an important platform for future biomarker identification and validation.

18 CRC screening in China has been implemented in several regions over the past
19 decades.[20, 21] However, high-quality evidence for the recommendation of CRC
20 screening in the Chinese population is still lacking and in high demand.[20] Therefore,
21 we plan to conduct a population-based, multicenter, randomized controlled trial

1
2
3
4 1 comparing colonoscopy, FIT, and a novel risk-adapted CRC screening strategy in the
5
6 2 Chinese population, with the following aims: 1) to establish a large-scale CRC
7
8
9 3 screening cohort with long-term follow-ups in China; 2) to evaluate the effectiveness
10
11 4 and cost-effectiveness of different CRC screening strategies in the Chinese population;
12
13
14 5 and 3) to construct a large epidemiological and clinical database and a biobank for
15
16
17 6 further studies.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1 **METHODS AND ANALYSIS**

2 **Study setting and design**

3 This prospective, multicenter, randomized controlled trial will compare multiple CRC
4 screening strategies in China. Participants who meet the study inclusion and exclusion
5 criteria will be recruited in five provinces in China. We aim to recruit at least 20,000
6 eligible participants at baseline. After obtaining signed informed consent, eligible
7 participants will be randomly allocated into one of the three CRC screening groups in
8 a 1:2:2 ratio (Figure 1). A 4-year screening phase (with 1-year baseline screening and
9 3 years of follow-up screening) will be conducted for all participants and a subsequent
10 passive follow-up phase will also be implemented until the scientific questions are
11 answered adequately. Detailed information about the follow-up is described in the
12 following section.

- 13 1) Colonoscopy group (N=4,000): participants are recommended to undergo a one-
14 time screening colonoscopy at baseline. Abnormal findings removed during
15 colonoscopy will be sent to pathology for further analysis. In the following years,
16 all participants will be interviewed to complete the follow-up questionnaire
17 annually.
- 18 2) FIT group (N=8,000): FITs are offered to the participants annually. Participants
19 with positive FIT findings are recommended to undergo a diagnostic colonoscopy.
20 Abnormal findings removed during colonoscopy will be sent to pathology for
21 further analysis.

1
2
3
4 1 3) Risk assessment group (N=8,000): Colorectal cancer risk will be assessed using
5
6 2 an established CRC risk stratification scoring system at baseline. For participants
7
8 3 at high risk of CRC, screening colonoscopy will be offered. For participants at
9
10 4 low risk of CRC, FITs will be offered and those with positive FIT results will be
11
12 5 recommended to undergo further colonoscopy. During the annual follow-ups,
13
14 6 participants with negative FIT results and those who have not had a screening
15
16 7 colonoscopy will complete another round of risk assessment and the same
17
18 8 screening procedures as at baseline will be offered. Participants who have already
19
20 9 undergone screening colonoscopy will be provided no further screening
21
22 10 intervention but the participants will complete a questionnaire annually during the
23
24 11 study period.
25
26
27
28
29
30
31
32

33 **Randomization and allocation procedure**

34
35
36 13 The randomization will be conducted in a centralized, controlled manner. The leading
37
38 14 institute (Cancer Hospital, Chinese Academy of Medical Sciences) is responsible for
39
40 15 the generation of the randomization scheme using a predefined seed from the statistical
41
42 16 software R. Before recruitment, both the staff responsible for recruitment at each site
43
44 17 and the participants will be blinded to the allocation results. The allocation results will
45
46 18 be revealed after successful registration of the subject in a web-based data system. At
47
48 19 the time of randomization, each patient will be assigned a unique Study Identification
49
50 20 Number (SIN), which will be used during the entire study period.
51
52
53
54
55
56
57

58 **Study population and recruitment**

59
60 22 Participants aged 50–74 years who live in the study region and are able to sign informed

1 consent are eligible for this study. The exclusion criteria are: 1) prior history of CRC;
2 2) prior history of colonic resection; 3) receipt of any kind of cancer-related therapy
3 (except for non-melanoma skin cancer); 4) prior colonic examination, including
4 colonoscopy, flexible sigmoidoscopy, computed tomography (CT) colonography, and
5 barium enema within 5 years; 5) prior history of fecal occult blood test and fecal DNA
6 test within 1 year; 6) symptoms of lower gastrointestinal tract disease warranting
7 colonoscopic evaluation, including a) more than one episode of rectal bleeding within
8 the past 6 months, b) documented iron deficiency anemia, and c) significant
9 documented unintentional weight loss (>10% of baseline weight) over 6 months; and
10 7) significant comorbidity that would preclude benefit from screening or pose a
11 significant risk to the performance of colonoscopy (e.g., severe lung disease, end-stage
12 renal disease, end-stage liver disease, severe heart failure, or recent diagnosis of cancer,
13 with the exception of non-melanoma skin cancer).

14 The recruitment procedures will include the following steps:

- 15 (1) Recruitment of potential participants aged 50–74 years in the selected
16 communities and checking for eligibility by trained study staff;
- 17 (2) Signed written informed consent obtained from the eligible participants by
18 trained study staff;
- 19 (3) Registration of the participant in the web-based data management system, SIN
20 assignment, and randomization results revealed; and
- 21 (4) Conducting respective intervention strategies per protocol;

1 **Interventions**

2 Colonoscopy

3 Standard clinical procedures for the screening colonoscopy will be followed, including
4 appointment; obtaining informed consent; routine blood testing for infectious diseases
5 including hepatitis B virus (HBV), hepatitis C virus (HCV), and human
6 immunodeficiency virus (HIV) infections (if required by the hospitals, otherwise not
7 implemented); distribution of bowel preparation drugs; diet control; anesthesia (if
8 required by the participants); and colonoscopy examination. The colonoscopies will be
9 performed by experienced endoscopists with more than 5 years of experience in
10 performing colonoscopy. Abnormal findings during colonoscopy will be carefully
11 checked under standard clinical procedures and tissue specimens will be collected for
12 further pathology diagnosis. Any findings during colonoscopy are required to be
13 documented photographically. Clinical information such as the examination duration,
14 sedation status, completeness of colonoscopy, bowel preparation status, complications,
15 polyp features (number, position, size, color, and shape), description of other abnormal
16 findings, as well as pathology diagnosis will be collected and documented in the web-
17 based data management system.

18 For quality control, an expert panel will be formed, including experienced endoscopists
19 and pathologists. Each year, a selection of colonoscopy and pathology documentation
20 will be assessed by the expert panel and review reports will be transferred to the
21 respective physicians regarding their performance.

1 Fecal immunochemical test (FIT)

2 FITs for human hemoglobin will be provided by the study staff to participants after
3 successful registration in this study. The FIT used in this study is a self-administered
4 qualitative test, providing an endpoint that is visually interpreted as positive or negative
5 by eye if the fecal hemoglobin concentration exceeds the manufacturer-specific
6 threshold (100 ng Hb/mL buffer, corresponding to 10 µg Hb/g feces). A previous pilot
7 analysis demonstrated that the sensitivities of 76% and 37%, respectively, for the
8 detection of CRC and advanced adenomas, at a specificity of 92% (data not publicly
9 available). The participants can submit the results to the study website along with the
10 picture of the test window or will be interviewed by the study staff regarding the test
11 results within 3 days of distributing the FIT. For participants with invalid test results,
12 new test devices will be provided until a result is available. Participants with confirmed
13 positive FIT results will be contacted and a follow-up colonoscopy will be arranged.

14 CRC risk assessment

15 This study will use an established CRC risk scoring system, the Asia-Pacific Colorectal
16 Screening (APCS) score.[22, 23] The APCS score is derived from five common risk
17 factors of CRC, including age, sex, family history of CRC in a first-degree relative,
18 smoking, and body mass index (BMI). In a previous study conducted in Hong Kong,
19 the sensitivity, specificity, positive predictive value, and negative predictive value of
20 the risk score for detecting advanced neoplasms were 33.3%, 81.0%, 5.17%, and 97.5%,
21 respectively, defining a score ≥ 4 as high risk for CRC.[23] Based on previous evidence,
22 we designed the risk score system and detailed information shown in Table 1. Generally,

1 the participants of the risk-adapted screening group will be asked to complete a
2 questionnaire including the above-mentioned risk factors. Participants with a score ≥ 4
3 are defined to be at high risk of CRC, while those with a score < 4 are defined to be at
4 low risk of CRC. Participants will be informed about their evaluation results and receive
5 the respective screening intervention as per the study protocol.

6 **Patient and public involvement**

7 During the process of recruitment, study staff will inform the participants about the
8 research question, study design, and screening intervention. The participants can quit
9 the study and withdraw their informed consent at any time based on their priorities,
10 experiences, or preferences. The participants and the public had no role in the study
11 design, recruitment, and conduct. All screening interventions will be provided to the
12 participants at no cost (compensated by this study), except for the subsequent
13 therapeutic costs which must be paid by the participants themselves. At the recruitment
14 phase, the study staff will inform the participants of the burden of the intervention and
15 potential subsequent therapeutic procedure. The study staff will also disseminate to the
16 participants a report summarizing the screening results.

18 **Biospecimen collection and handling**

19 Participants who require colonoscopy will be invited to donate stool, saliva, and blood
20 samples prior to colonoscopy. Standard Operating Procedures (SOPs) regarding
21 biospecimen collection, handling, and storage have been formulated and will be
22 followed.

1 For stool samples, collection devices (sample collection vials, ice bags, isothermal bags,
2 and operation brochures) will be distributed. On the day before the colonoscopy, the
3 participants will be suggested to collect raw stool samples before taking bowel cleaning
4 drugs for colonoscopy. The participants will be recommended to store the samples in
5 the freezer or in the isothermal bags with ice bags until transported to the hospital. The
6 samples will be stored at -80°C immediately upon receipt for future use.

7 For saliva samples, participants will be provided with sample collection tubes
8 containing oral DNA stabilization buffer during their visit to the hospital before the
9 colonoscopy. Study staff will guide the participants on the saliva sample collection
10 procedure. The collected samples will be aliquoted immediately and stored at -80°C for
11 future use.

12 Approximately 10 mL venous blood samples (including 5 mL
13 ethylenediaminetetraacetic acid anticoagulated blood and 5 mL non-anticoagulated
14 blood) will be drawn from the participants during their visit to the hospital before
15 colonoscopy. Under the SOPs, the blood samples are to be centrifuged, aliquoted, and
16 stored at -80°C for future use.

17 **Follow-up**

18 The study will conduct both active and passive follow-up. For the active follow-up, all
19 the participants will be interviewed by trained study staff by telephone call, home visit,
20 or other contact methods for the collection of information such as physical examination,
21 health status, and outcome. For the passive follow-up, linkage data from the cancer

1 registry system, death surveillance system, and medical insurance and claim databases
2 will be used to track the outcome of the participants.

3 **Contamination evaluation**

4 During the study period, the study team will contact the participants to evaluate the
5 status of CRC beyond the study protocol. The extra screening examinations attended
6 by the participants during the study period are not allocated by randomization and,
7 therefore, may introduce bias to the study results. To evaluate the contamination status
8 of this study, all participants whose screening findings are negative will complete one
9 round of questionnaire interview in the fourth year of the study. Information regarding
10 the history of diagnostic or colonic examination screening will be collected and
11 assessed. We anticipate controlling the contamination rate to be below 10%. The final
12 analysis report will consider the contamination when estimating the effects of screening.

13 **Outcome measures**

14 The primary outcome is the detection rate of advanced colorectal neoplasia (CRC and
15 advanced adenoma). The secondary outcomes include the rates of CRC mortality,
16 detection of any neoplasm, compliance, and complications.

17 **Data collection**

18 Epidemiological risk factor investigation

19 A standardized epidemiological questionnaire will be administered by trained
20 interviewers to all participants to investigate the risk factors of CRC. Information
21 including sociodemographic factors, history of bowel disease and clinical treatment,

1 living habits, disease history, and family history of cancer will be collected and stored
2 in a web-based data management system.

3 Health economic information

4 A comprehensive health economic evaluation will be conducted. Questionnaires
5 including the EuroQol five dimensions questionnaire (EQ-5D) and EQ-5D-5L will be
6 used to measure the health state of the participants. The direct costs of materials,
7 equipment, personnel, drug, and other resources will be collected from all participating
8 sites to estimate the cost-effectiveness of different screening strategies in this clinical
9 trial.

10 **Data monitoring committee**

11 A data monitoring committee comprising epidemiologists, endoscopists, pathologists,
12 and colorectal surgeons will monitor data collection and analyses. All data will be
13 transmitted to the Central Data Management Team at the National Cancer Center of
14 China/Cancer Hospital Chinese Academy of Medical Sciences, where the databases are
15 constructed and analyses are performed. In addition, any adverse events, such as
16 perforation, and bleeding, will be recorded in standardized forms by the study sites and
17 will also be reported to the Ethics Committee for their records.

18 **Statistical Considerations**

19 Sample sizes

20 Sample sizes were calculated based on the evaluation of primary outcomes; i.e., the
21 detection rate of advanced colorectal neoplasia. The hypothesis was that this rate in the
22 risk-adapted screening group was superior to that of the FIT group and non-inferior to

1 that of the colonoscopy group. According to previous studies, the reference advanced
2 neoplasia detection rates of colonoscopy, FIT, and risk-adapted screening groups were
3 6.5%, 1.8%, and 5.0%, respectively.[13, 24] We assumed compliance rates of 50–70%
4 for colonoscopy, 60–90% for FIT, and 60–90% for the risk-adapted screening strategy
5 and an overall loss-to-follow-up rate of 10%. For the comparison between the risk-
6 adapted screening strategy and the FIT groups for different scenarios of compliance
7 rates, the largest sample size needed was 6,550 at a significance level of $\alpha=0.05$, power
8 of 0.8, and superiority margin (δ) of -0.005. For comparison between the risk-adapted
9 screening and colonoscopy groups, assuming respective compliance rates of 85% and
10 60%, the required sample sizes were 6,032 and 3,016, respectively, for a significance
11 level of $\alpha=0.05$, power of 0.8, and non-inferiority margin (δ) of -0.001. Therefore, the
12 sample sizes in this study design (4,000 for the colonoscopy group, 8,000 for the FIT
13 group, and 8,000 for the risk-adapted screening group) will accomplish the study
14 hypotheses.

15 **Statistical analyses**

16 The primary outcome analysis will be comparisons of histologically-confirmed CRC
17 and advanced adenoma between the three intervention arms, taking the compliance rate
18 into consideration. Intention-to-treat and per-protocol analyses will be conducted. For
19 secondary outcomes, the mortality rate will be calculated as the ratio of the number of
20 deaths due to CRC to the person-years at risk for each group. Person-years will be
21 estimated from the time of randomization to the diagnosis date of CRC, death, or
22 censoring at the end of the study. The incidence rate will be estimated similarly. Chi-

1 square and t-tests will be used to compare categorical and continuous variables between
2 the two groups, respectively. The Cox proportional hazards regression model will be
3 adopted to examine the differences in incidence and mortality between different
4 screening groups. For health economic evaluations, Markov models will be developed
5 to evaluate the cost-effectiveness of different CRC screening strategies in China.
6 Statistical software such as SAS (version 9.2; SAS Institute, Cary, NC, USA), R
7 (version 3.4.1, R Foundation for Statistical Computing, Vienna, Austria), and TreeAge
8 Pro 2016 (TreeAge Software, Inc., MA, USA), will be used for the data analyses.

9 10 **Ethics and dissemination**

11 This study was approved by Ethics Committee of the National Cancer Center/Cancer
12 Hospital, the Chinese Academy of Medical Sciences, and Peking Union Medical
13 College (approved number: 18-013/1615) and the protocol was registered in the
14 Chinese Clinical Trial Registry (registration number: ChiCTR1800015506).

15 The results of the study will be submitted for publication to peer-reviewed journals and
16 conferences following the Consolidated Standards of Reporting Trials guidelines. The
17 results will be discussed by policy and decision makers. Access to the detailed research
18 plan, participant-level dataset, and code for statistical analysis will be granted based on
19 reasonable requests after the publication of the study.

20 **Trial status**

21 This screening trial is currently in the participant enrolment phase. A total of 1,600
22 eligible participants have been randomized and are under respective CRC screening as

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 of August 2018. We anticipate the full analysis to be finalized in December 2021.

For peer review only

1 **DISCUSSION**

2 Our study aims to evaluate the effectiveness and cost-effectiveness of three CRC
3 screening strategies in China. To our knowledge, this is the first large-scale randomized
4 controlled trial on CRC screening based on a community population in China.
5 Colonoscopy is the gold standard for CRC screening and FIT is the most widely used
6 non-invasive CRC screening test. However, the magnitude of the effect of colonoscopy
7 and FIT in population-based CRC screening is uncertain due to a lack of evidence from
8 randomized controlled trials. To date, three large-scale randomized controlled trials
9 (SCREESCO, CONFIRM, and COLONPREV) have compared colonoscopy or FIT
10 screening regarding CRC incidence and mortality.[25-28] All three trials are ongoing
11 and being conducted in Europe and North America. Our study will be the first large-
12 scale CRC screening trial in Asia. In addition, we also include a novel risk-adapted
13 screening strategy that incorporates risk assessment with established screening methods.
14 Our study will provide strong evidence on the effectiveness and feasibility of different
15 strategies for CRC screening in China.

16 In recent years, the burden of CRC has been increasing in East-Asia due to changes in
17 diet and Westernized lifestyles.[29] Countries including China, Japan, and South Korea
18 have implemented organized screening programs. For instance, in Japan, the CRC
19 screening program initiated in 1992 uses FIT as the main screening method, the cost of
20 which is covered by the national health insurance.[30] In China, individuals aged 40–
21 74 years are screened with FOBT or colonoscopy based on clinical risk indexes in some

1
2
3
4 1 regions but not the entire country.[20] Furthermore, the most appropriate techniques
5
6 2 for different populations in China are still under debate. The results of our study will,
7
8
9 3 therefore, provide high-level evidence to design CRC screening strategies for China
10
11 4 and will also provide an essential reference for other countries.
12
13
14

15 5 We plan to finish the baseline recruitment and baseline screening for this study before
16
17 6 June 2019 and will have a total of three rounds of screening intervention FIT and risk-
18
19 7 adapted screening groups. Long-term passive follow-up will also be conducted to
20
21 8 determine the health outcomes of the participants for the evaluation of the long-term
22
23 9 effect of CRC screening. Our study has several strengths. First, the prospective
24
25 10 randomized design will minimize selection bias and provide high-level evidence
26
27 11 compared to those of other designs such as cross-sectional studies. In addition, except
28
29 12 for active follow-up, we will also implement passive follow-up using multiple resources
30
31 13 such as cancer registry, death surveillance system, and medical insurance and claim
32
33 14 databases to track the outcomes of the study participants. We will also construct a large
34
35 15 biobank using prospectively collected specimens. This biobank will serve as an
36
37 16 essential platform for biomarker identification and validation for further investigations.
38
39
40
41
42
43
44
45
46
47

48 17 The major challenges of this study are control of loss to follow-up and quality control
49
50 18 of a multi-center project. To address such concerns, we will employ experienced study
51
52 19 staff to regularly contact and visit the participants. Moreover, a health education
53
54 20 campaign will be conducted to improve health literacy by means of lectures, videos,
55
56 21 advertisements, and social media. For quality control, we will build an expert panel
57
58
59
60

1 including experts in epidemiology, endoscopy, pathology, and surgery. A capacity
2 training workshop will be held annually and a selection of study reports will be
3 reviewed to ensure study quality.

4 In summary, this large-scale multi-center randomized controlled trial will compare
5 three CRC screening strategies. Successful implementation of this study will provide
6 strong evidence on the effectiveness and cost-effectiveness of CRC screening and
7 provide an essential reference for policy-makers to design national screening programs.

AUTHORS' CONTRIBUTIONS

HC, NL, and MD designed the study protocol; HC and NL drafted the manuscript; and JS, JR, CL, YZ, ZJ, ZZ, and MD critically reviewed and revised the manuscript. All authors read and approved the final manuscript.

FUNDING STATEMENT

This work was supported by the CAMS Innovation Fund for Medical Sciences (2017-I2M-1-006) and the National Natural Science Foundation of China (81703309). The funders had no role in the study design and conduct; data collection, management, analysis, and interpretation; manuscript preparation, review, or approval; and the decision to submit the manuscript for publication.

COMPETING INTERESTS

The authors declare that they have no competing interests.

ACKNOWLEDGEMENTS

The authors thank the participating sites (Zhejiang Cancer Hospital, Anhui Provincial Cancer Hospital, Xuzhou Cancer Hospital, Hunan Cancer Hospital, and Yunnan Cancer Hospital), the Centers for Disease Control and Prevention of the participating cities, and the community staff and participants for their contributions. We also thank Dr. Prudence Carr for the English proofreading of this manuscript.

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, and Jemal A, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*, 2018. 68(6): 394-424.
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, and He J, Cancer statistics in China, 2015. *CA Cancer J Clin*, 2016. 66(2): 115-32.
3. Zorzi M, Fedeli U, Schievano E, Bovo E, Guzzinati S, Baracco S, Fedato C, Saugo M, and Dei Tos AP, Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test. *Gut*, 2015. 64(5): 784-90.
4. Brenner H, Stock C, and Hoffmeister M, Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. *Bmj*, 2014. 348: g2467.
5. Hewitson P, Glasziou P, Watson E, Towler B, and Irwig L, Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. *Am J Gastroenterol*, 2008. 103(6): 1541-9.
6. Brenner H, Kloor M, and Pox CP, Colorectal cancer. *Lancet*, 2014. 383(9927): 1490-502.
7. Schreuders EH, Ruco A, Rabeneck L, Schoen RE, Sung JJ, Young GP, and Kuipers EJ, Colorectal cancer screening: a global overview of existing programmes. *Gut*, 2015. 64(10): 1637-49.
8. Whitlock EP, Lin JS, Liles E, Beil TL, and Fu R, Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. *Ann Intern Med*, 2008. 149(9): 638-58.
9. Senore C, Inadomi J, Segnan N, Bellisario C, and Hassan C, Optimising colorectal cancer screening acceptance: a review. *Gut*, 2015. 64(7): 1158-77.
10. Robertson DJ, Kaminski MF, and Bretthauer M, Effectiveness, training and quality assurance of colonoscopy screening for colorectal cancer. *Gut*, 2015. 64(6): 982-90.
11. Tinmouth J, Lansdorp-Vogelaar I, and Allison JE, Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know. *Gut*, 2015. 64(8): 1327-37.
12. Lin JS, Piper MA, Perdue LA, Rutter CM, Webber EM, O'Connor E, Smith N, and Whitlock EP, Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *Jama*, 2016. 315(23): 2576-94.
13. Chiu HM, Ching JY, Wu KC, Rerknimitr R, Li J, Wu DC, Goh KL, Matsuda T, Kim HS, Leong R, Yeoh KG, Chong VH, Sollano JD, Ahmed F, Menon J, and Sung JJ, A Risk-Scoring System Combined With a Faecal Immunochemical Test Is Effective in Screening High-Risk Subjects for Early Colonoscopy to Detect Advanced Colorectal Neoplasms. *Gastroenterology*, 2016. 150(3): 617-25.e3.
14. Provenzale D, Jasperson K, Ahnen DJ, Aslanian H, Bray T, Cannon JA, David DS, Early DS, Erwin D, Ford JM, Giardiello FM, Gupta S, Halverson AL, Hamilton SR, Hampel H, Ismail MK, Klapman JB, Larson DW, Lazenby AJ, Lynch PM, Mayer RJ, Ness RM, Rao MS, Regenbogen SE, Shike M, Steinbach G, Weinberg D, Dwyer MA, Freedman-Cass DA, and Darlow S, Colorectal Cancer Screening, Version 1.2015. *J Natl Compr Canc Netw*, 2015. 13(8): 959-68; quiz 68.
15. Armaroli P, Villain P, Suonio E, Almonte M, Anttila A, Atkin WS, Dean PB, de Koning HJ, Dillner

- 1
2
3 L, Herrero R, Kuipers EJ, Lansdorp-Vogelaar I, Minozzi S, Paci E, Regula J, Tornberg S, and
4 Segnan N, European Code against Cancer, 4th Edition: Cancer screening. *Cancer Epidemiol*,
5 2015. 39 Suppl 1: S139-52.
6
7 16. Win AK, Macinnis RJ, Hopper JL, and Jenkins MA, Risk prediction models for colorectal cancer:
8 a review. *Cancer Epidemiol Biomarkers Prev*, 2012. 21(3): 398-410.
9
10 17. Jung YS, Park CH, Kim NH, Park JH, Park DI, and Sohn CI, A combination of clinical risk
11 stratification and fecal immunochemical test is useful for identifying persons with high priority
12 of early colonoscopy. *Dig Liver Dis*, 2018. 50(3): 254-59.
13
14 18. Cubiella J, Digby J, Rodriguez-Alonso L, Vega P, Salve M, Diaz-Ondina M, Strachan JA, Mowat
15 C, McDonald PJ, Carey FA, Godber IM, Younes HB, Rodriguez-Moranta F, Quintero E, Alvarez-
16 Sanchez V, Fernandez-Banares F, Boadas J, Campo R, Bujanda L, Garayoa A, Ferrandez A, Pinol
17 V, Rodriguez-Alcalde D, Guardiola J, Steele RJ, and Fraser CG, The fecal hemoglobin
18 concentration, age and sex test score: Development and external validation of a simple
19 prediction tool for colorectal cancer detection in symptomatic patients. *Int J Cancer*, 2017.
20 140(10): 2201-11.
21
22 19. Dickinson BT, Kisiel J, Ahlquist DA, and Grady WM, Molecular markers for colorectal cancer
23 screening. *Gut*, 2015. 64(9): 1485-94.
24
25 20. Goss PE, Strasser-Weippl K, Lee-Bychkovsky BL, Fan L, Li J, Chavarri-Guerra Y, Liedke PE,
26 Pramesh CS, Badovinac-Crnjevic T, Sheikine Y, Chen Z, Qiao YL, Shao Z, Wu YL, Fan D, Chow
27 LW, Wang J, Zhang Q, Yu S, Shen G, He J, Purushotham A, Sullivan R, Badwe R, Banavali SD,
28 Nair R, Kumar L, Parikh P, Subramanian S, Chaturvedi P, Iyer S, Shastri SS, Digumarti R, Soto-
29 Perez-de-Celis E, Adilbay D, Semiglazov V, Orlov S, Kaidarova D, Tsimafeyeu I, Tatishchev S,
30 Danishevskiy KD, Hurlbert M, Vail C, St Louis J, and Chan A, Challenges to effective cancer
31 control in China, India, and Russia. *Lancet Oncol*, 2014. 15(5): 489-538.
32
33 21. Guo C, Liu Q, and Dai M, [Colorectal cancer screening: situation and prospect]. *Zhonghua Yu*
34 *Fang Yi Xue Za Zhi*, 2015. 49(5): 377-80.
35
36 22. Sung JY, Wong MCS, Lam TYT, Tsoi KKF, Chan VCW, Cheung W, and Ching JYL, A modified
37 colorectal screening score for prediction of advanced neoplasia: A prospective study of 5744
38 subjects. *J Gastroenterol Hepatol*, 2018. 33(1): 187-94.
39
40 23. Yeoh KG, Ho KY, Chiu HM, Zhu F, Ching JY, Wu DC, Matsuda T, Byeon JS, Lee SK, Goh KL, Sollano
41 J, Rerknimitr R, Leong R, Tsoi K, Lin JT, and Sung JJ, The Asia-Pacific Colorectal Screening score:
42 a validated tool that stratifies risk for colorectal advanced neoplasia in asymptomatic Asian
43 subjects. *Gut*, 2011. 60(9): 1236-41.
44
45 24. Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, Ahlquist DA, and Berger
46 BM, Multitarget stool DNA testing for colorectal-cancer screening. *N Engl J Med*, 2014. 370(14):
47 1287-97.
48
49 25. Kaminski MF, Bretthauer M, Zauber AG, Kuipers EJ, Adami HO, van Ballegooijen M, Regula J,
50 van Leerdam M, Stefansson T, Pahlman L, Dekker E, Hernan MA, Garborg K, and Hoff G, The
51 NordICC Study: rationale and design of a randomized trial on colonoscopy screening for
52 colorectal cancer. *Endoscopy*, 2012. 44(7): 695-702.
53
54 26. Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas A, Andreu M, Carballo F, Morillas
55 JD, Hernandez C, Jover R, Montalvo I, Arenas J, Laredo E, Hernandez V, Iglesias F, Cid E,
56 Zubizarreta R, Sala T, Ponce M, Andres M, Teruel G, Peris A, Roncales MP, Polo-Tomas M, Bessa
57 X, Ferrer-Armengou O, Grau J, Serradesanferm A, Ono A, Cruzado J, Perez-Riquelme F, Alonso-
58
59
60

- 1
2
3 Abreu I, de la Vega-Prieto M, Reyes-Melian JM, Cacho G, Diaz-Tasende J, Herreros-de-Tejada
4 A, Poves C, Santander C, and Gonzalez-Navarro A, Colonoscopy versus fecal immunochemical
5 testing in colorectal-cancer screening. N Engl J Med, 2012. 366(8): 697-706.
6
7 27. CONFRIM trial at <http://www.clinicaltrials.gov/ct2/show/NCT01239082> (accessed 28 April
8 2018).
9
10 28. Screesco trial at <http://www.clinicaltrials.gov/ct2/show/NCT02078804> (accessed 28 April
11 2018).
12
13 29. Sung JJ, Lau JY, Goh KL, and Leung WK, Increasing incidence of colorectal cancer in Asia:
14 implications for screening. Lancet Oncol, 2005. 6(11): 871-6.
15
16 30. Saito H, Colorectal cancer screening using immunochemical faecal occult blood testing in Japan.
17 J Med Screen, 2006. 13 Suppl 1: S6-7.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Risk factors and respective proposed points for Asia-Pacific Colorectal Screening (APCS) scores to be used in this trial

Risk factor	Criteria	Points
Age (years)	<50	0
	50-69	1
	≥70	2
Sex	Female	0
	Male	1
Family history of colorectal cancer in a first-degree relative	Absent	0
	Present	1
Smoking	No	0
	Current or past	1
BMI	<23	0
	≥23	1

Abbreviations: BMI, Body mass index, calculated as weight (kg)/height²(meters²)

Figure Legend

Figure 1. Standard Protocol Items for Randomized Trials (SPIRIT) flow diagram of the study design

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. SPIRIT flow diagram of the study design

338x190mm (133 x 120 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Page
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	4
	2b	All items from the World Health Organization Trial Registration Data Set	4
Protocol version	3	Date and version identifier	NA
Funding	4	Sources and types of financial, material, and other support	22
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	22
	5b	Name and contact information for the trial sponsor	NA
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	22
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	11
Introduction			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	5
	6b	Explanation for choice of comparators	5 and 6
Objectives	7	Specific objectives or hypotheses	5 and 6
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	7

Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	8
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	10
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	8 and 9
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	10
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	10
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	11
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	14
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	8
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	15
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	10

Methods: Assignment of interventions (for controlled trials)

Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	9
---------------------	-----	--	---

1	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central	9
2	concealment		telephone; sequentially numbered, opaque, sealed envelopes),	
3	mechanism		describing any steps to conceal the sequence until interventions are	
4			assigned	
5				
6				
7	Implementation	16c	Who will generate the allocation sequence, who will enrol participants,	9
8			and who will assign participants to interventions	
9				
10	Blinding	17a	Who will be blinded after assignment to interventions (eg, trial	9
11	(masking)		participants, care providers, outcome assessors, data analysts), and	
12			how	
13				
14		17b	If blinded, circumstances under which unblinding is permissible, and	9
15			procedure for revealing a participant's allocated intervention during	
16			the trial	
17				

18 **Methods: Data collection, management, and analysis**

19				
20	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other	15
21	methods		trial data, including any related processes to promote data quality (eg,	
22			duplicate measurements, training of assessors) and a description of	
23			study instruments (eg, questionnaires, laboratory tests) along with	
24			their reliability and validity, if known. Reference to where data	
25			collection forms can be found, if not in the protocol	
26				
27				
28		18b	Plans to promote participant retention and complete follow-up,	13
29			including list of any outcome data to be collected for participants who	
30			discontinue or deviate from intervention protocols	
31				
32	Data	19	Plans for data entry, coding, security, and storage, including any	15
33	management		related processes to promote data quality (eg, double data entry;	
34			range checks for data values). Reference to where details of data	
35			management procedures can be found, if not in the protocol	
36				
37	Statistical	20a	Statistical methods for analysing primary and secondary outcomes.	16
38	methods		Reference to where other details of the statistical analysis plan can be	
39			found, if not in the protocol	
40				
41		20b	Methods for any additional analyses (eg, subgroup and adjusted	16
42			analyses)	
43				
44		20c	Definition of analysis population relating to protocol non-adherence	16
45			(eg, as randomised analysis), and any statistical methods to handle	
46			missing data (eg, multiple imputation)	
47				
48				

49 **Methods: Monitoring**

50				
51	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role	11
52			and reporting structure; statement of whether it is independent from	
53			the sponsor and competing interests; and reference to where further	
54			details about its charter can be found, if not in the protocol.	
55			Alternatively, an explanation of why a DMC is not needed	
56				
57				
58				
59				
60				

1		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	NA
2				
3				
4				
5				
6	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	15
7				
8				
9				
10	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	NA
11				
12				
13				
14	Ethics and dissemination			
15				
16	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	17
17				
18				
19	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	17
20				
21				
22				
23				
24	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	10
25				
26				
27				
28		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	13
29				
30	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	9
31				
32				
33				
34				
35	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	22
36				
37				
38	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	9
39				
40				
41				
42	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	NA
43				
44				
45	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	NA
46				
47				
48				
49				
50				
51		31b	Authorship eligibility guidelines and any intended use of professional writers	NA
52				
53				
54		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	NA
55				
56				
57				
58				
59				
60				

Appendices

Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	NA
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	13

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.